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Abstract
With rapid advancements in sequencing technology, we now have the ability to sequence
the entire human genome, and to quantify expression of tens of thousands of genes
from hundreds of individuals. This provides an extraordinary opportunity to learn
phenotype relevant genomic patterns that can improve our understanding of molecular
and cellular processes underlying a trait. The high dimensional nature of genomic data
presents a range of computational and statistical challenges. This dissertation presents
a compilation of projects that were driven by the motivation to efficiently capture
gene regulatory patterns in the human transcriptome, while addressing statistical
and computational challenges that accompany this data. We attempt to address two
major difficulties in this domain: a) artifacts and noise in transcriptomic data, and b)
limited statistical power.
First, we present our work on investigating the effect of artifactual variation in
gene expression data and its impact on trans-eQTL discovery. Here we performed
an in-depth analysis of diverse pre-recorded covariates and latent confounders to
understand their contribution to heterogeneity in gene expression measurements.
Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from
the Genotype Tissue Expression (GTEx) project. Finally, we characterized two
trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid.
Second, we present a principal component based residualization method to correct
gene expression measurements prior to reconstruction of co-expression networks. In
this work, we demonstrated theoretically, in simulation, and empirically, that principal
ii
component correction of gene expression measurements prior to network inference can
reduce false positive edges. Using data from the GTEx project in multiple tissues, we
showed that this approach reduced false discoveries beyond correcting only for known
confounders.
Third, we present a multi-study integration approach to identify universal tran-
scriptional patterns underlying epithelial to mesenchymal transition (EMT) across
different cancer types. With informed statistical analysis and functional validation,
we identified consensus ranked universal EMT genes. This gene list consisted of a)
known EMT genes, b) genes studied in a subset of carcinomas, unknown in prostate
cancer, and c) novel unknown EMT and cancer genes such as C1orf116.
Finally we present methods to integrate co-expression signals across multiple
human RNA-seq data to reconstruct networks with increased power. First, we
considered multiple aggregation strategies to build context-agnostic networks using
data from recount2. These networks captured ubiquitous patterns of gene co-expression
shared across tissues and cell types. Next, we briefly describe a hierarchical mixture
model groupNet that leverages signal from multiple datasets to learn the structure
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Innovations in engineering and technology have played a remarkable role in discovery
and clinical translation in medicine (https://aimbe.org/milestones-of-innovation/).
The completion of the Human Genome Project (HGP) in 2003 was a notable break-
through, with its main goals of a) determining a draft sequence of the 3 billion
nucleotides that make up the human genome and b) identifying genes that it contains.
This was the culmination of a large-scale, interdisciplinary, thirteen-years-long effort
involving scientists with diverse expertise ranging from biology, chemistry, and genetics
to mathematics and computer science. The publication of the sequence of the human
genome in April 2003 was a groundbreaking achievement with the potential to revolu-
tionize medicine[1]. Since then, rapid advancements in sequencing technologies have
made it possible to sequence the human genome and quantify expression measurements
for every human gene – thereby presenting the opportunity to investigate patterns of
gene expression and regulatory structure at the genome-wide level. Effective utilization
of these data also presents a range of computational and statistical challenges.
1
Background
Cellular and tissue level organization of the human body
Humans are complex multi-cellular organisms, and this complexity increases with
increasing levels of cellular organization. Cells are the smallest independent functional
entities of the human body. For example cardiomyoctyes are cells that make up the
cardiac muscle. A group of similar types of cells that work together to perform a
specific function come together to form a tissue (e.g. cardiac muscle tissue). An
organ is composed of a group of tissues that perform specific physiological functions.
The heart, for instance, is the organ composed of cardiac muscle tissue that pumps
blood throughout the body. Finally, an organ system constitutes multiple organs that
together perform systemic physiological functions. The circulatory system consists of
the organs that transport nutrients and oxygen to different parts of the body. These
levels of organization increase in complexity starting from cells to tissues to organs to
organ systems to a complete organism.[2]
Figure 1-1. Structural organization of human body.
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Central Dogma of molecular biology
Each cell of every multi-cellular organism, including humans, contains a copy of its
genome. A genome carries the complete set of genetic information required for normal
functioning and survival of an organism. It is often also referred as the ‘blueprint’ of
an organism. It is made of Deoxyribonucleic Acids (DNA) that contains instructions
to make proteins and other molecules required for normal cell functioning. The
information in DNA is stored in the form of a code that contains four nucleic acid
bases: adenine, cytosine, guanine, thymine. Parts of DNA that code for functional
end products such as RNA (Ribonucleic Acid) and protein are called genes. The
central dogma of molecular biology explains the information flow from DNA to its
end products through gene expression. There are two key stages of gene expression:
• Transcription – the process during which information in DNA is converted to
RNA
• Translation – the process during which information from RNA is converted to
amino acid sequences, which are the building blocks of proteins [3]
Similar to DNA, the information in RNA is also stored as a code in the form of four
nucleic acid bases: adenine, cytosine, guanine, and uracil. Historically, RNA was
viewed as an intermediate messenger between genes and proteins. While messenger
RNA, also called as mRNA serves as an intermediate molecule, there exists a diverse
group of non-protein coding RNAs such as lincRNAs, miRNAs, piRNAs, snoRNAs,
rRNA, and tRNA that are functional end products by themselves[4]. Despite containing
the same exact copy of the genome, different cells and tissues in the human body have
different phenotypes and perform very diverse functions. Regulatory programs recruit
gene products in the form of proteins and RNAs to generate specific transcriptional
patterns thus enabling cells, tissues, and organs to perform distinct functions. This
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Figure 1-2. Central dogma of molecular biology.
control can be exerted at various stages of gene expression including genetic, epigenetic,
transcriptional, and post-transcriptional regulation[5–7].
Gene expression and phenotypic variation
For many years after the discovery of the structure of DNA in 1953 scientists turned
their focus to understanding the functions of protein coding genes and how mutations
in these genes alter quantities and structures of the resulting proteins[8]. Defects in
gene regulatory programs can alter expression patterns in cells and tissues which can
eventually lead to clinically relevant phenotypes. It is critical to understand regulation
of gene expression and how it changes or adapts in response to genetic, chemical, or
environmental stimulus. Therefore, identifying genes or genetic variants associated
with phenotypic variance can provide insight into understanding cellular and molecular
processes involved in trait manifestation.
Differential gene expression analysis
Differential gene expression analysis (DGE) involves identifying genes that show
significantly different expression patterns between conditions or are associated with a
4
phenotype of interest such as diseased vs normal patients, treatment vs control, cell
types, tissues, developmental stage, or other conditions.
Statistical hypothesis tests that are commonly used to identify differentially expressed
genes can be grouped into two categories:
• Parametric: These tests are based on assumptions that the data being tested
follow particular statistical distribution. For example, t-test and ANOVA
assumes that the data follows a gaussian distribution.
• Non-parametric: These tests do not make any assumptions about the data.
Wilcoxon rank-sum test is an example of a rank based non-parametric test
Usually in these tests, there are two hypotheses: a) the null hypothesis (H0) that states
that there is no statistical difference between the expression of the gene between the
two groups and b) an alternate hypothesis (H1) that states that there is a statistically
significant difference in the expression of the gene between the two groups.
Example:
Given that we are interested in using a t-test to test if a gene g is differentially
expressed between individuals with cancer (C) and normals (N), we test:
H0 : µC = µN (1.1)
H1 : µC ̸= µN (1.2)
Here, µC and µN correspond to the mean expression of gene g in cancer patients and
normal patients.
Identification of differentially expressed genes can extend our understanding of genetic
and molecular processes involved in phenotypic variation. Further, genes identified
can be used in downstream analysis such as building a relevant prediction model or
identifying disease subtypes.
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Genetic variation and transcriptomic regulation
The most frequent variants in the human genome are Single Nucleotide Variants
(SNV). These are substitutions that affect a single base pair. A SNV that is present in
a sufficiently large fraction of a population is called a Single Nucleotide Polymorphism
(SNP). Genome wide association studies (GWAS) utilize large scale population data
to identify germline SNPs associated with a trait. Since the first GWAS on age related
macular degeneration in 2005, there has been an abundance of trait associated variants
reported in literature. However, a traditional GWAS does not provide a framework
to link these statistical associations to genes or functional biological mechanisms
underlying a trait; this remains a daunting task. Genetic variants can have a series
of cascading effects first relayed at the molecular level from mRNA to protein to
pathways which can then impact cellular and physiological processes underlying traits
and diseases.
The majority of trait-associated genetic variants discovered by GWAS have been
Figure 1-3. Cis-eQTLs and trans-eQTLs.
found in the non-coding regions of the genome. In response, over the last 10 years
there have been several large scale efforts to improve understanding of the functional
effect of genetic variation on gene expression and its impact within and across tissues.
Genetic variants that are quantitatively associated with amounts of gene expression
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are called expression quantitative trait loci(eQTL)[7, 9, 10]. Two types of eQTLs are
of common interest, as seen in Figure 1-3:
• cis-eQTLs: genetic variants that quantitatively affect expression of genes on the
same molecule of the chromosome.
• trans-eQTLs: genetic variants that quantitatively affect expression of gene
located on a different molecule of chromosome.
While there has been significant progress in understanding the mechanism of cis-
genetic effect on gene expression, gene expression regulation mediated by trans-eQTLs
is not completely understood[11]. Trans-regulatory effects can be mediated through
cis-regulation affecting expression of a nearby gene, which would then in turn alter
expression of a distant gene. Trans-eQTLs can provide a framework to understand the
cascading effect of genetic and molecular signalling and implication in diseases1-4.
Figure 1-4. Trans-eQTLs.
Co-expression networks
Genes are known to interact with each other to relay signal across biological pathways
and processes. This form of signal transduction is a critical piece in the foundation
of human biology. [12–14]. This is evident by concerted expression patterns among
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genes observed in empirical data. Networks are often used to model such interactions
among entities in complex systems.
A co-expression network is an undirected graph where genes are represented as
nodes and a functional relationship between genes is represented as an edge between
nodes. Gene networks can identify patterns of expression indicative of functional
and regulatory relationships among genes. These can be used to determine critical
pathways and genes underlying a trait or disease [15]. A complete understanding
of in vivo functional interactions among genes is lacking for most cell types, tissues,
or disease relevant contexts. Therefore, discovering functional relationships between
genes can improve our understanding of genetic and molecular bases of gene regulation.
These functional relationships can also provide insights into the cascade of molecular
events critical for disease manifestation in humans under a variety of conditions.
Challenges
A primary concern for nearly all modalities of genomic measurements is that the
data is inherently noisy. Transcriptomic measurements are routinely affected by a
wide-range of artifacts and unwanted heterogeneity that is not the primary signal of
interest [16–19]. Structured artifactual signal by covariates such as RNA integrity
number of a sample, proportion of GC nucleotides in a gene, or batches in which
samples are processed adds biased noise in gene expression measurements. These
biases in the data are sometimes correlated with outcomes or variables of interest, that
can lead to inaccurate conclusions[16]. Most scientific data also contains unbiased
random (white) noise that does not have a pattern, but can yet affect statistical power
to detect signal. In this dissertation, we attempt to address the impact of biased noise
in gene expression data. Additionally, limited statistical power is another major hurdle
in computational genomics. Low probability of finding true signal, overestimation of
effect sizes leading to false positives, and lack of reproducibility are some of the major
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issues that result from under-powered studies. While we have the ability to measure
expression for over 40,000 genes, the number of gene expression samples available is
usually limited to a few hundred samples which is insufficient to make consistent and
statistically robust conclusions.
Thesis outline
Amidst noisy, under-powered, and heterogeneous genomic data, this thesis presents
carefully informed statistical and machine learning approaches to elucidate the under-
lying basis of transcriptional regulation along with some examples of its implication
in human disease. Towards this, we describe: a) methods to analyze and address
the impact of confounding on gene expression data in trans-eQTL mapping and
co-expression networks, and b) multi-study integration based approaches to leverage
power across multiple studies to improve signal estimation in differential expression
analysis and gene co-expression networks.
• In chapter 2 using GTEx data, we perform an in-depth analyses of diverse
confounding variables that contribute to gene expression heterogeneity and affect
mapping of eQTLs. Next, we identify genetic variants with distal regulatory
effects on gene expression (trans-eQTLs) and characterize some trait associated
trans-eQTLs. This work was published in Nature and involved joint effort of
multiple trainees and PIs in the GTEx consortium. Trans-eQTL analysis was
joint work with Brian Jo, Yuan He, and Benjamin Strober [20].
• In chapter 3, we present a principal component based residualization approach
to correct gene expression data prior to reconstruction of co-expression networks.
This was joint work with Claire Ruberman and was published in Genome Biology
[21].
• In chapter 4, we present a multi-study integration based approach to identify
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global transcriptional regulatory patterns underlying epithelial to mesenchymal
transition (EMT) phenotype in cancer. In this work, with informed statistical
analysis and functional validation, we identified global expression patterns in
epithelial to mesenchymal transition (EMT) phenotype in cancer and discovered
candidate regulatory genes. This work was published in BMC cancer [22].
• In chapter 5, we present an aggregation-based approach to reconstruct context-
agnostic gene co-expression networks using large scale transcriptomic data from
recount2[23]. We find influential genes and relationships involved in critical
processes shared across different biological contexts such as cell cycle, mitosis,
etc. This is joint work with Prashanthi Ravichandran.
• In chapter 6, we present a mixture model based probabilistic method to recon-
struct context specific gene co-expression networks. This can be particularly
useful when working with publicly available open source datasets, which often
have missing context-specific meta-data. Using preliminary simulation analyses
we show that our method can identify and group studies by relevant context.




Distant regulatory effects of
genetic variation across human
tissues
While we have successfully mapped cis-eQTLs for a majority of genes, discovery
of replicable trans-eQTLs remains a challenging task. Trans-eQTL discovery is
particularly impacted by: a) small effect sizes, b) artifact-induced false positives, and
c) statistical power. Most studies have attempted trans-eQTL discovery in limited cells
or tissue types [24–26]. It is known that genetic regulation of gene expression varies
across tissues and cell types. Context-specific regulation of gene expression recruits
specific transcriptional programs that allow different types of cells and tissues to
perform distinct biological functions. In this work, we performed trans-eQTL mapping
across 44 human tissues from the Genotype Tissue Expression (GTEx) Project to
understand distant regulatory effects of genetic variation on gene expression.
Contributions
This chapter describes the trans-eQTL analyses from the GTEx project that I co-led
along with Brian Jo, Yuan He, and Benjamin Strober. My main contributions to this
work included:
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• Investigation of latent factors anticipated to capture artifactual variation in gene
expression that were used for eQTL mapping, and its impact on trans-eQTL
discovery
• Replication of trans-eQTLs in thyroid with TCGA Thyroid cancer data
• Investigation of functional role of eVariants and eGenes in thyroid and skeletal
muscle, and performed relevant analyses
This work was published in [20].
Introduction
The human genome encodes instructions for the regulation of gene expression, which
varies both across cell types and across individuals. Recent large-scale studies have
characterized the regulatory function of the genome across a diverse array of cell types
each from a small number of samples[27–29]. Measuring how gene regulation and
expression vary across individuals has further expanded our understanding of healthy
tissue function and the molecular origins of complex traits and diseases[7, 9, 24, 25,
30, 31]. However, to date, these studies have been conducted in limited, accessible cell
types, thus restricting the utility of these studies in informing regulatory biology and
human health.
In this study, we associate genetic variants with gene expression levels from the
GTEx v6p release. For the first time, we identify trans-eQTLs across 16 tissues
and highlight their increased tissue specificity relative to cis-eQTLs. We evaluate
trans-eQTLs to characterize their functional characteristics, genomic context, and
relationship to disease-associated variation.
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Study design
The GTEx project has created a reference resource of gene expression from ’normal’,
non-diseased tissues. Every tissue sample was examined histologically. If the tissue was
non-diseased and in the normal age-range of the donor, the sample was accepted. RNA
was isolated from postmortem samples in an ongoing manner as donors were enrolled
in the study. For this data release, 44 sampled regions or cell lines were considered,
each from at least 70 donors and thereby considered suitable for eQTL analysis: 31
solid-organ tissues, ten brain subregions including duplicates of two regions (cortex
and cerebellum), whole blood, and two cell lines derived from donor blood and skin
samples. We hereafter refer to these tissues, regions, and cell lines as the tissues used
in eQTL analysis. A total of 7,051 samples from 449 donors represent the GTEx v6p
analysis freeze (Fig. 1a). This is 4.3 times more samples than reported in the GTEx
pilot phase[32]. DNA was genotyped at 2.2 million sites and imputed to 12.5 million
sites (11.5 million autosomal and 1 million X chromosome sites) using the multi-ethnic
reference panel from 1000 Genomes Project Phase 1 v3[33]. Sampled donors were
83.7% European American and 15.1% African American. Whole genome sequencing
was performed for 148 donors to a mean coverage greater than 30×, and all donors were
exome-sequenced to a mean coverage over captured exons of 80×. The resulting data
provide the deepest survey of individual and tissue-specific gene expression to date,
enabling a comprehensive view of the impact of genetic variation on gene expression.
All data are available from dbGaP (accession phs000424.v6.p1) with multiple publicly
available data views available from the GTEx Portal (www.gtexportal.org).
Methods
No statistical methods were used to predetermine sample size. The experiments were




All human donors were deceased donors. Informed consent was obtained for all donors
via next-of-kin consent to permit the collection and banking of de-identified tissue
samples for scientific research. The research protocol was reviewed by Chesapeake
Research Review Inc., Roswell Park Cancer Institute’s Office of Research Subject
Protection, and the institutional review board of the University of Pennsylvania. Com-
plete descriptions of the donor enrollment and consent process, as well as biospecimen
procurement, methods, sample fixation, and histo-pathological review procedures
were previously described[32, 34]. Briefly, whole blood along with fresh skin sam-
ples was collected from each donor and shipped overnight to the GTEx Laboratory
Data Analysis and Coordination Center (LDACC) at the Broad Institute for DNA
genotyping, RNA expression, and culturing of lymphoblastoid and fibroblast cells.
Two adjacent aliquots were then prepared from each sampled tissue and preserved in
PAXgene tissue kits. One of each paired sample was embedded in paraffin (PFPE)
for histopathological review. The second was shipped to the LDACC for processing
and molecular analysis. Brains were collected from approximately 1/3rd of the donors
and were shipped on ice to the brain bank at the University of Miami where 11 brain
sub-regions were sampled and flash-frozen. These samples were also shipped to the
LDACC for processing and analysis.
All DNA genotyping was performed on blood-derived DNA samples unless un-
available, in which case a tissue-derived DNA sample was substituted. RNA was
extracted from all tissues and RNA sequencing was performed on all samples with
a RIN score of 5.7 or higher and with at least 500 ng of total RNA. Nucleic acid
isolation protocols and sample QC metrics applied are as described in the previous
study[32] (Supplementary Information in [20]).
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Data production
Non-strand specific, polyA+ selected RNA-seq libraries were generated using the Illu-
mina TruSeq protocol. Libraries were sequenced to a median depth of 78 million 76-bp
paired-end reads. RNA-seq reads were aligned to the human genome (hg19/GRCh37)
using TopHat (v1.4) based on GENCODE v19 annotations. This annotation is
available on the GTEx Portal (gencode.v19.genes.v6p model.patched contigs.gtf.gz).
Gene-level expression was estimated as reads per kilobase of transcript per million
mapped reads (RPKM) using RNA-SeQC on uniquely mapped, properly paired reads
fully contained with exon boundaries and with alignment distances ≤ 6. Samples with
less than 10 million mapped reads or with outlier expression measurements based on
the D-statistic were removed.
DNA from 450 donors was genotyped using Illumina Human Omni 2.5M and
5M Beadchips. Genotypes were phased and imputed with SHAPEIT2[35] and
IMPUTE2[36], respectively, using multi-ethnic panel reference from 1000 Genomes
Project Phase 3[37]. Variants were excluded from analysis if they: (1) had a call rate
< 95%; (2) had minor allele frequencies < 1%; (3) deviated from Hardy-Weinberg
Equilibrium (P < 1.0 × 10−6); or (4) had an imputation info score less than 0.4. The
final genotyped and imputed array VCF (file format v4.1) for autosomal variants
contained genotype posterior probabilities for each of the three possible genotypes for
11,552,519 variants across 450 GTEx donors. The dosages of the alternative alleles
relative to the human reference genome hg19 were used as the genotype measure for
subsequent eQTL analysis. In addition to array-based genotyping, 148 and 524 donors
were whole genome and exome-sequenced respectively. Additional details on genotyp-
ing, imputation, and sequencing can be found in the Supplementary Information of
[20]
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RNA-seq data processing and correction for technical con-
founders
We conducted trans-eQTL mapping within the 44 tissues with at least 70 samples
each. Only genes with ten or more donors with expression estimates > 0.1 RPKM and
an aligned read count of six or more within each tissue were considered significantly
expressed and used for trans-eQTL mapping. Within each tissue, the distribution
of RPKMs in each sample was quantile-transformed using the average empirical
distribution observed across all samples. Expression measurements for each gene in
each tissue were subsequently transformed to the quantiles of the standard normal
distribution. The effects of unobserved confounding variables on gene expression were
quantified with PEER[17], run independently for each tissue. Fifteen PEER factors
were identified for tissues with fewer than 150 samples; 30 for tissues with sample sizes
between 150 and 250; and 35 for tissues with more than 250 tissues. The covariates
that were most consistently associated with PEER factors include factors related
to parameters of donor death, ischaemic time, RIN, and sequencing quality control
metrics. In addition, we have observed that little, if any, genetic signal is present in
the PEER factors.
To further understand the effect of PEER correction on gene expression and
trans-eQTL mapping in each tissue, we compared the PEER factors from each tissue
to sample and donor specific covariates. First, we fit a linear model between gene
expression data E and loadings PEER factors L. Using this model, we obtained the
expression component Ef , that was removed by PEER correction as given below:
E = µ + β · L
Ef = E − Er
We tested the association of Ef with different sample specific and donor specific
covariates. In each tissue, we first selected covariates with more than one unique
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entry after excluding missing values. For covariates with categorical entries, we only
considered categories with more than 20 observations. Samples that did not meet this
criteria were considered as missing values. The covariates that were included in this
analysis had at least 50 observations (without missing values) in at least 31 tissues
based on the above criteria. Finally, for each selected covariate we fit a linear model
with expression component removed by PEER factors, Ef as the dependent variable
and the covariate C as:
Ef = µ + β · C
From this model, we computed the proportion of variance of Ef explained by the
covariate as the adjusted R2:
Adjusted R2 = R2 −
[︃
(1 − R2) p
p − n − 1
]︃
Trans-eQTL mapping
Matrix eQTL[38] was used to test association of all autosomal variants (MAF > 0.05)
with all gene transcripts restricted to variants and genes lying on different chromosomes
in each tissue independently using an additive linear model. For trans-eQTL mapping,
we tested variants for association with expression of only protein coding or lincRNA
genes. We included, as covariates, the three genotype PCs, genotyping platform, sex,
and PEER factors estimated from expression data in Matrix eQTL when performing
association testing. The correlation between variant and gene expression levels was
evaluated using the estimated t-statistic from this model. The corresponding FDR
was estimated using Benjamini-Hochberg FDR correction[38, 39] separately within
each tissue and using permutation analysis. For all trans association tests, we applied
stringent quality control to account for potential false positives due to RNA-seq




We quantified tissue-specificity and tissue-sharing of trans-eQTLs using Meta-Tissue[40]
which extends Metasoft[41], a meta-analysis package, by using a mixed effects model
for eQTL sharing that accounts for correlation of expression between tissues driven by
overlapping donors.
All genotypes and gene expression quantification estimates were adjusted for
covariates in accordance to the single tissue analysis as described in the previous
sections. For each variant-gene pair, we calculated mixed model effect size estimates
in each expressed tissue, thereby adjusting for partial sharing of signal between tissues.
These effect size estimates were used in meta-analysis using Metasoft[41] to assess
tissue-specificity of each variant-gene pair. For each variant-gene pair tested, Meta-
Tissue estimates a global P-value of association and the posterior probability that an
effect exists in a tissue (m-value). For computational feasibility, the MCMC method
was used to approximate the exact solution.
To supplement this analysis, we also performed multi-tissue analysis using a
hierarchical FDR control[42] for trans-eQTLs analysis (Supplementary Information at
[20])
Co-localization of GWAS and eQTL associations
In order to assess the probability that molecular traits as estimated by cis- and trans-
eQTLs, and physiological traits as estimated by GWAS share the same causal variant,
we applied the coloc R package[43]. For each GWAS, we approximated the number
of independent loci by extracting variants with at least genome-wide significance (P
< 5 × 10−8) and farther than 1 MB away from all other variants of higher statistical
significance. For each genome-wide significant variant, we extracted the list of all
eGenes (q-value < 0.05 for cis-eGene) within 1 Mb for coloc analyses. For each eGene,
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we excluded any variants without either eQTL or GWAS association statistics (effect
size estimate, standard error and P-value). We obtained reference information such as
MAF, sample size, and case-to-control proportions (in case of binary traits) for each
variant whenever available otherwise, study-wide estimate was used as a proxy. We
defined a region or an eGene as having evidence of co-localization when region- or
gene-based posterior probability of co-localization (PP.H4.ABF) P P 4
P P 3+P P 4 > 0.9.
TCGA thyroid RNA-seq analysis
To replicate trans-eVariants in thyroid, we used Thyroid Carcinoma (THCA) RNA-seq
and genotype array data from The Cancer Genome Atlas (TCGA). Filtering out
tumor normal and metastatic samples, we restricted our analysis to 498 primary
tumor samples. Next, after log transforming RNA-seq RSEM measurements, we
ensured that expression of each gene follows a Gaussian distribution by projecting
each gene expression levels to the quantiles of a standard normal. To account for
noise and confounding factors in RNA-seq measurements, we corrected the data
by 35 PEER factors. Using a linear model while adjusting for 35 PEER factors
with MatrixeQTL, we tested the effect of each variant on chr 9 position 100600000 -
100670000 on expression levels of all trans genes. We used the Benjamini-Hochberg
method to correct for multiple hypotheses testing (assessed only among 24 variants
tested). Genes with FDR ≤ 0.1 were called as trans-eGenes.
Data and biospecimen availability
Genotype data from the GTEx v6p release are available in dbGaP (study acces-
sion phs000424.v6.p1; www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000424.v6.p1). The VCFs for the imputed array data are in phg000520.v2.GTEx
MidPoint Imputation.genotype-calls-vcf.c1.GRU.tar (the archive contains a VCF for
chromosomes 1-22 and a VCF for chromosome X). Allelic expression data is also
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available in dbGap. Expression data (read counts and RPKM) and eQTL input files
(normalized expression data and covariates for 44 the tissues) from the GTEx v6p
release are available from the GTEx Portal (http://gtexportal.org). eQTL results
are available from the GTEx Portal.
Results
Trans-eQTL mapping 44 human tissues
To identify trans-eQTLs, we tested for association between every protein-coding or
lincRNA gene and all autosomal variants where the gene and variant were on different
chromosomes. To minimize false positives in trans-eQTL detection, we controlled
for the same observed and inferred confounders as optimized for cis-eQTL discovery,
and further removed genes with poor mappability, variants in repetitive regions, and
trans-eQTLs between pairs of genomic loci that show evidence of RNA-seq read
cross-mapping due to sequence similarity[44]. Applying this approach, we found 673
trans-eQTLs at a 10% genome-wide FDR. This includes 112 distinct loci (R2 ≤ 0.2)
and 93 unique genes (94 total gene associations, including an eGene detected in both
testis and thyroid) in 16 tissues (Table 2-I, Figure 2-1). An alternative approach
to quantify FDR at the gene level identified 46 genes at 10% FDR, with estimated
q-values less than 0.4 for all 94 gene associations identified using the genome-wide
FDR (Table 2-I).
Testis had the most trans-eGenes, with 35 eGenes in 157 samples (Figure 2-1),
reflecting the elevated number of expressed genes (16,853 protein-coding genes and
4,362 lincRNA genes) and cis-eGenes (6,796 genes). We found statistical power to
detect additional associations in these restricted tests, such as the test restricted to
cis-eVariants. Our results indicate that increases in sample sizes will continue to yield
additional eQTLs, especially in the trans-eQTL setting where statistical power is the
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Genome wide Gene-level FDR
Tissue No. of samples No. of trans-eGenes No. of trans-eVariants No. of trans-eGenes
Muscle – Skeletal 361 9 43 4
Whole Blood 338 1 2 1
Skin – Sun Exposed (Lower leg) 302 6 16 3
Adipose – Subcutaneous 298 2 7 0
Lung 278 2 2 2
Thyroid 278 21 181 3
Cells – Transformed fibroblasts 272 1 10 1
Nerve – Tibial 256 0 0 1
Esophagus – Mucosa 241 3 11 3
Artery – Aorta 197 1 1 1
Skin – Not Sun Exposed (Suprapubic) 196 1 1 2
Stomach 170 0 0 2
Colon – Transverse 169 2 10 2
Testis 157 35 267 16
Pancreas 149 2 12 1
Adrenal Gland 126 1 1 1
Brain – Putamen (Basal ganglia) 82 3 11 2
Vagina 79 4 27 1
Total unique 93 602 46
Table 2-I. Trans-eVariant and trans-eGene discoveries for genome-wide FDR
control, and trans-eGene discoveries for gene-level FDR control. Each tissue with
non-zero values is included as a row; the columns include the number of samples for that
tissue, followed by the number of unique trans-eGenes and trans-eVariants identified in the
genome-wide tests and the number of unique trans-eGenes found using gene-level FDR
calibration. Ultimately the set of 673 trans-eQTLs identified in the genome-wide approach
yielded 602 unique trans-eVariants.
major limitation.
Correction for technical confounders in trans-eQTL mapping
To account for hidden batch effects and other potential confounders in the gene
expression data, we used the Probabilistic Estimation of Expression Residuals (PEER)
[45] method to estimate a set of latent covariates for gene expression levels for each
tissue type. The number of PEER factors was selected to maximize ciseGene discovery,
and this optimization was performed for three sample size bins: tissues with fewer
than 150 samples, tissues with ≤ 150 and < 250 samples, and tissues with ≥ 250
samples. Specifically, the eQTL discovery pipeline was run in increments of 5 PEER
factors for 12 tissues spread across the sample size bins using a 100 permutations.
Based on these results, and to avoid potential overfitting, 15, 30, and 35 PEER factors
were selected, respectively for the three sample size bins(Figure 2-2). We did not
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Figure 2-1. Trans-eQTL discovery. Number of trans-eQTLs (x-axis) per tissue (y-axis),
with sample size indicated by point size.
have sufficient statistical power or sufficient numbers of trans-eQTLs to tune the
number of PEER factors for trans-eQTL analysis without facing potential overfitting
to spurious signal. Post-hoc analysis demonstrated no clear trend in number of trans-
eQTL discoveries as we varied the number of PEER factors removed. Further, failure
to remove confounding factors could result in false positive transeQTL associations.
Therefore, we opted to use the settings determined by the analysis of cis-eQTLs for
the trans-eQTL analysis as well. This aggressive correction, explained 59-78% of total
variance in gene expression levels, however may lead to false negatives, reducing the
signals for broad effect trans-eVariants with many target genes. Indeed, several loci
with numerous associations that were found in uncorrected data disappeared after
controlling for PEER factors. We also found that the trans-eVariants detected before
PEER correction were enriched for association with known technical confounders
(Figure 2-3).
We tested association of PEER factors from each tissue with known technical and
biological covariates recorded for each sample and donor. PEER factors from each
tissue were correlated with known technical and biological covariates recorded for
each sample and donor (Figure 2-4,2-5). The covariates that were most consistently
associated with PEER factors include factors related to parameters of donor death,
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Figure 2-2. Identification of the optimal number of PEER factors for hidden
covariate correction during eQTL analyses. The number of PEER factors was chosen
to maximize eGene discovery and this optimization was performed for three sample size
bins: tissues with < 150 samples, tissues with ≥150 and <250 samples, and tissues with
≥250 samples available. The eQTL discovery pipeline was run with increments of 5 PEER
factors for the 12 tissues shown using a reduced number of permutations (100 instead of
the adaptive 1000-10000 used for all other analyses). Based on these results and to avoid
potential overfitting, 15, 30, and 35 PEER factors were selected respectively.
ischemic time, RIN, and sequencing quality control metrics. Nucleic acid isolation
and library construction batches and total sequencing depth were also moderately
associated. Across tissues, the median percent variance explained (PVE) by RIN of
the set of PEER factors used for correction was 0.05, with a maximum PVE of 0.13 in
heart − left ventricle. The PVE by these covariates of the expression data after PEER
correction was negligible-median 4 × 10−3 for RIN. Similarly, after correction, the
detected trans-eVariants show little association with known covariates. For example,
the two tissues with the most trans-eQTLs, thyroid and testis, show no association
between RIN and any trans-eVariant at FDR 50%.
Tissue-specific patterns of trans-eQTLs
We observed much greater tissue specificity for trans-eQTLs than a set of FDR-matched
cis-eQTLs (Figure 2-6). This observation was robust to choices of m-value threshold




















Figure 2-3. Trans-eVariants lost after PEER correction are enriched for associa-
tion with known covariatesTrans-eVariants that were detected in raw expression data
but lost after PEER correction were tested for association with known sample covariates
using a linear model. This quantile-quantile plot shows - log10(P-values) of trans-eVariants
lost after PEER correction as compared to matched random variants, with each tissue
shown as a distinct color. Combined across tissues, the association - log10(P-values) are
significantly larger than random (Wilcoxon rank sum test; P ≤ 2.2 × 10−16).
across three or more tissues at m-value > 0.9, 25.3% of FDR-matched cis-eQTLs were
shared. Extensive tissue-specificity for trans-eQTLs was also observed based on a
hierarchical approach for FDR control[46], where we found no trans-eQTLs shared
across more than one tissue (Table2-II). Our estimate of increased tissue specificity
for trans-eQTLs agreed with the minimal sharing of trans effects reported in previous
eQTL studies with fewer tissues[25, 47, 48], and dramatically exceeds what would be
expected based on replication between tissues for cis-eQTLs of matched minor allele
frequency (MAF) and effect size (Wilcoxon rank sum test; P ≤ 2.2 × 10−16 for all
choices of replication FDR). Given greater tissue-specificity of trans-eQTLs, we note
that heterogeneity in cellular composition of bulk tissue samples is one important
confounder that may reduce power to detect trans-eQTLs, or even lead to false positive
associations[24]. Despite high tissue-specificity, we did observe a small number of
24
Figure 2-4. Sample covariates associated with PEER factors in each tissue. For
each tissue, adjusted (R2 ) reflecting the proportion of variance explained by each sample-
specific covariate, for the entire PEER component removed from the expression data. Each
cell reflects variance explained for a tissue/covariate pair (color scale at bottom). Grey
cells represent pairs with insufficient data for estimation.
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Figure 2-5. Donor covariates associated with PEER factors in each tissue. For
each tissue, adjusted (R2 ) reflecting the proportion of variance explained by each donor-
specific covariate, for the entire PEER component removed from the expression data. Each
cell reflects variance explained for a tissue/covariate pair, color scale at bottom. Grey cells
represent pairs with insufficient data for estimation.
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tissue-shared trans-eQTLs, including rs7683255, which was moderately associated
in trans with NUDT13 across most tested GTEx tissues with consistent direction
of effect. We also found examples of trans-eQTLs shared across a subset of related
tissues, such as an association between rs60413914 and RMDN3, a gene with increased
expression in brain, and for which the trans-eQTL had moderate effects in all tested





















# tissues with m-value > 0.5
Figure 2-6. Tissue specific patterns of trans-eQTLs. Distribution of the number
of tissues having Meta-Tissue m < 0.5 for the top variant for each trans-eGene at 50%
FDR, and FDR-matched, randomly selected cis-eGenes (also 50% FDR). cis-eGenes were
matched for discovery tissue to the trans-eGenes
Trans-eQTLs and complex disease associations
Overlaps between GWAS associations and eQTLs have provided important insights into
regulatory genes and variants for a wide range of complex traits and diseases[30, 49].
Genetic variants associated with complex traits have been suggested to be enriched for
trans-eQTLs[24, 50–52]. Accordingly, we performed trans-eQTL mapping restricting
to variants associated with a complex trait in a GWAS. In this analysis, across the
44 tissues, we found 29 trans-eQTL associations involving 24 unique variants and 25
unique genes, each specific to a single tissue. There were more trans-eVariants at
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Tissue No. of samples No. of trans-eGenes No. of trans-eVariants
Whole Blood 338 1 1
Skin – Sun Exposed (Lower leg) 302 2 3
Lung 278 2 2
Thyroid 278 2 2
Esophagus – Mucosa 241 3 3
Artery – Aorta 197 1 1
Skin – Not Sun Exposed (Suprapubic) 196 1 1
Heart – Left Ventricle 190 1 1
Testis 157 4 5
Colon – Sigmoid 124 1 1
Brain – Cortex 96 1 1
Brain – Putamen (Basal ganglia) 82 1 1
Total unique 20 22
Table 2-II. Trans-eVariant and trans-eGene discoveries with hierarchical FDR
control. Only tissues with non-zero discoveries are shown. The three-level hierarchical
procedure (see Online Methods) performs FDR control across tissues. More specifically, it
controls the FDR of eVariants, the average proportion of false variant-gene associations
across all eVariants, and a weighted average of false tissue discoveries for the selected
variant-gene pairs (weighted by the size of the eVariant and eGene sets). The procedure
was applied after LD pruning.
FDR ≤ 0.5 with association in at least one tissue when testing was restricted to trait-
associated variants compared with random variants matched by MAF and distance
to TSS (Fisher's exact test, P ≤ 1.3 × 10−3). Among trait-associated variants with
trans-eQTL effects, we found two genome-wide significant trans-eVariants at the 9q22
locus (rs7037324 and rs1867277, R2 = 0.74) with thyroid-specific associations in trans
with TMEM253 and ARFGEF3 (P ≤ 2.2 × 10−16 for both with rs1867277; Figure
2-7). The 9q22 locus has previously been linked to multiple thyroid-specific diseases
including goiter, hypothyroidism, and thyroid cancer[53–55], and LoF mutations in
a thyroid-specific TF at this locus, FOXE1, manifest as ectopic thyroid tissue or
cleft palate in developing mice[56]. However, the mechanism of any cis-effects of
these trans-eVariants remains uncertain from the GTEx data. A post-hoc analysis
demonstrated that PEER correction removed broad regulatory signals from the 9q22
locus, particularly from cis- and trans-eQTL signals for FOXE1. In PEER corrected
data, cis- and trans-eQTL signals co-localized for another cis-eGene in 9q22, C9orf156,















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































= 0.31 = 0.23
Figure 2-7. Characterization of complex trait-associated trans-eQTLs. (a) Asso-
ciation of rs1867277 with PEER corrected TMEM253 expression levels (P ≤ 2.2 × 10−16).
(b) Quantile-quantile plot of associations between 19 variants in the 9q22 locus and all
genes in GTEx thyroid gene expression levels, compared to 19 random variants from the
same chromosome, and associations between 23 variants in the 9q22 locus and all genes
in TCGA thyroid tumor expression data, compared to 23 random variants from the same
chromosome. (c) Network depicting cis- and trans-regulatory effects of rs1012793 mediated
through interferon regulatory factor 1 (IRF1). Rs1012793 affects expression of IRF1 in cis
and PSME1 and ARTD10 in trans (box plots). IRF1 is significantly co-expressed with the
trans-eGenes (scatter plots). (d) Cis and trans association significance of variants within
1 Mb of IRF1 TSS in chromosome 5 locus with cis-eGene IRF1 (blue) and trans-eGene
PSME1 (brown), showing concordant signal across the locus.
analysis of the PEER-corrected data supported C9orf156 regulating TMEM253 (P
≤ 1.3 × 10−9) and ARFGEF3 (P ≤ 2.1 × 10−11) based on trans-eVariant rs1867277. In
contrast, FOXE1 had weak Mendelian randomization support in the PEER-corrected
data. Despite the ambiguity of cis-mediation, the locus is one of the strongest trans-
eQTL signals in GTEx. We further replicated both the broad regulatory effect and
specific target genes of this locus in 498 primary thyroid cancer RNA-seq samples
from The Cancer Genome Atlas (TCGA; Figure 2-7b)[57].
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Figure 2-8. Broad trans-regulatory locus 9q22 in thyroid tissue. (a) FOXE1
expression is thyroid-specific. (b) Correlation between FOXE1 expression levels and
thyroid PEER factors compared to 100 random genes. For every gene, absolute correlation
was sorted in decreasing order. The correlation of FOXE1 with the 5th, 6th, 7th, and
8th PEER factors was significantly higher than the correlation of random genes at those
rank ordered PEER factors (empirical P ≤ 0.05). (c-e) Variants in the chr 9q22 locus
were enriched for association with genes on other chromosomes in thyroid carcinomas
compared to randomly selected variants nearby randomly selected genes. We used variants
that were found within 35 Kb upstream or downstream of the gene TSS. (f) rs10759975
is associated with trans-eGene TMEM253. (g) rs10759975 is associated with trans-eGene
ARFGEF3. (h) rs10759975 shows cis association with C9orf156. (i) rs10759975 is weakly
associated in cis with FOXE1.
and rs1012793; R2 = 0.84) were associated in trans with PSME1 (P ≤ 1.1 × 10−11)
and ARTD10 (P ≤ 7.8 × 10−10), and in cis with IRF1 (P ≤ 2.0 × 10−10; Figure 2-7c),
a transcription factor known to facilitate regulation of interferon-induced immune-
response[58–61]. Both variants are associated with circulating fibrinogen levels[62]
influencing muscle injury, Duchene muscular dystrophy (DMD), multiple sclerosis, and
rheumatoid arthritis[63–66], and have been shown to drive fibrosis in DMD, where
they promote expression of IL-1β and TGF-β57. These variants were moderately
associated with numerous genes in skeletal muscle (50 trans-eGenes at 20% FDR,
assessed only among the three variants; Figure 2-9a). Additional candidate target
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Figure 2-9. Trait-associated variants in skeletal muscle near interferon regulatory
factor IRF1. (a) rs1012793 has broad regulatory impact in skeletal muscle. (b) Gene set
enrichment for potential trans-eGene targets (identified at P ≤ 0.001) of skeletal muscle
5q31 locus.
(Figure 2-9b). Mendelian randomization analysis supported IRF1 regulating PSME1
(P ≤ 3.1 × 10−8) and ARTD10 (P ≤ 1.9 × 10−7) through cis-eVariant rs2706381
with a consistent direction of effect (Figure 2-7c). Moreover, the cis-eQTL signal for
IRF1 co-localized with the trans-eQTL signals for both trans-eGenes (Figure 2-7c;
posterior probability > 0.99)[43]. Together, these results suggest that cis-regulatory
loci affecting IRF1 are regulators of interferon-responsive inflammatory processes
involving genes including PSME1 and ARTD10, with implications for complex traits
specific to muscle tissue.
Discussion
Since the initial sequencing of the human genome, extensive effort has been devoted
to the characterization of genome function and phenotypic consequences of genetic
variation. Describing the effects of genetic variation on gene expression levels across
tissues is a critical but challenging component of this goal. Here, we describe advances
enabled by the GTEx project v6p data, which provide a comprehensive survey of
gene expression and the impact of genetic variation on gene expression across diverse
human tissues. While considering the effect of artifacts and latent confounders, we
report trans-eQTLs in 18 tissues and discovered that trans-eQTL effects tended to be
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tissue-specific and were correspondingly more enriched in enhancer regions. Further,
we characterize two trait associated trans-eQTLs, one in skeletal muscle, and another
in thyroid tissue - along with a potential mechanism of cis-mediated trans genetic
regulation. Our work provides comprehensive characterization of trans-eQTLs across
human tissues, which contribute to an improved understanding of tissue-specific
cellular mechanisms of regulatory genetic variation.
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Chapter 3




Gene co-expression networks seek to identify transcriptional patterns indicative of
regulatory relationships between genes[12, 13, 15]. These are not yet fully character-
ized for most species, tissues, and disease-relevant contexts. Therefore reconstructing
co-expression networks from high-throughput measurements is of common interest.
However, accurate reconstruction of such networks remains a challenging problem.
Though some specialized methods for reconstruction of co-expression networks do
consider confounding signals within their model[68, 69], routinely used network learn-
ing methods [70, 71] do not directly account for technical and unwanted biological
effects known to confound gene expression data. Despite this, many studies do not
employ any form of data correction, or correct only for known confounders prior to
network reconstruction (Table A-I). These artifacts influence gene expression measure-
ments, often introducing spurious correlations between genes[18, 19, 19, 72]. These
correlations are often inferred as relationships between genes, leading to inaccurate
network structure and erroneous conclusions in downstream analyses[19, 68, 69, 73, 74].
Therefore, it is critical to correct gene expression data for unwanted biological and
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technical variation without eliminating signal of interest before applying standard
network learning methods.
In this chapter, we present a principal component based residualization method to
correct gene expression data prior to building co-expression networks. We demonstrate
theoretically, in simulation, and empirically, that principal component correction of
gene expression measurements prior to network inference can reduce false discoveries.
Using data from the GTEx project in multiple tissues, we show that this approach
reduces false discoveries beyond correcting only for known confounders.
Contributions
I co-led this project along with Claire Ruberman. My main contributions to this work
include:
• Design and analysis of empirical experiments
• Design and analysis of simulation experiments along with Claire Ruberman
The work described in this chapter was published in [21]. The text of this chapter is a
slight modification of the published work.
Methods
All analyses was performed using R and scripts are available on github [75]
Principal component based correction of gene expression
Using a permutation based approach as described in [76], we first determined the
number of principal components p to correct the data for with the num.sv function
in the Bioconductor package sva (Table 3-I). By permuting expression of each gene,
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num.sv identifies the number of top principal components that contribute to non-
random expression variance in the data. Next we compute the principal component
loadings L of the standardized expression matrix with singular value decomposition
(SVD).Using a linear model, we regressed the top p principal components (p as
determined by num.sv) on the each gene Ei, from the expression data and computed
the residuals Eiˆ :
Ei = µi + βi × L1:p (3.1)
Êi = Ei − [µi + (βi × L1:p)] (3.2)









Table 3-I. Number of principal components removed in each tissue.
Simulated example
We construct a network with eight nodes that represent genes and three edges that
represent conditional dependencies between the genes. Next, we simulate 10,000 obser-
vations from a multivariate normal distribution encoding the conditional dependencies
corresponding to three edges as non-zero entries in the precision matrix (Figure 1a).
To introduce confounding in the data, we simulate a sample specific term by drawing
a random vector of 10,000 observations from a standard normal distribution, and
add a scalar multiple of that to genes 2 through 6 (Figure 1d). Finally, to correct
35
the data, we regress out the first principal component from the confounded data
(Figure 1g). We used graphical lasso to reconstruct networks using the three versions
of the data. The code for this simulation example and network reconstruction can be
found at: https://github.com/leekgroup/networks_correction/blob/master/
publication_rmd/simulation_example_fig1/figure1.Rmd
Simulation with scale-free networks
We simulated 10,000 observations from a multivariate gaussian distribution that en-
codes conditional dependencies across 100 genes corresponding to a sale-free network.
This was obtained with B-A algorithm implemented in ‘huge.generator‘ in ‘huge’ R
package. Next to introduce confounding in the data, we simulated a sample specific
term from a standard normal distribution, and added a scalar multiple of that to
genes 20 genes in the data. To correct the data, we regressed out the first principal
component from the confounded data. We used graphical lasso to reconstruct networks
using the three versions of the data.
We also simulated 350 observations from a multivariate gaussian distribution that
encodes conditional dependencies across 5000 genes - sample and gene numbers similar
to those in our empirical experiments. We simulated two sample specific terms, and
two gene specific terms to introduce weighted confounding to 1500 genes multiplied
by a scalar constant. This confounding data was corrected by regressing 2 PCs (as
estimated by the permutation procedure). We used graphical lasso to reconstruct
networks with three versions of data.




Determining sample specific estimate of GC bias
Studies have shown that GC content of genes have significant impact on sequencing
read coverage in DNA-seq and RNA-seq experiments. This eventually introduces
sample specific biases in expression quantification. To quantify the effect of GC bias,
using transcript level fasta files from Gencode v25 we first computed the GC% of each
transcript by:
GC%(T ) = (#G + #C)(#A + #T + #G + #C) (3.3)
We summarized GC content of genes, by averaging over all transcripts belonging to






Next using a linear model, we obtain sample specific estimates of GC content of genes:
Ei = µ + βi × G (3.5)
where, Ei is the vector of expression values of all genes in sample i, G is the GC
content for each gene and βi is the estimate of GC bias for sample i.
Network reconstruction using GTEx data
Based on sample size, we used gene expression RNA-seq data from eight tissues in
the GTEx project[77] that included whole blood, lung, skeletal muscle, tibial artery,
sun-exposed skin, tibial nerve, subcutaneous adipose, and thyroid (Table 3-II). In each
tissue we filtered for non-overlapping protein coding genes that had scaled expression
(counts scaled by the total coverage of the sample) of at least 0.1 25% of total number
of observations. Next, we log2 transformed the scaled gene expression data, and
performed the following steps to select the most variable 5000 genes across all tissues,











Table 3-II. Tissue sample size.
(a) Select genes expressed in all five tissues.
(b) For each tissue, assign a rank to each gene by variance, such that the most
variable gene is ranked first and least variable gene is ranked in last.
(c) Using the ranked list of genes from five tissues, assign an average rank to each
gene across five tissues.
(d) Select the top 5000 genes based on average rank for network inference with
WGCNA and graphical lasso.
We used multiple approaches to correct gene expression data from each tissue
individually as described below:
• Residuals from RIN/Exonic Rate/ GC bias: Using a linear model, we regressed
the RNA integrity number (RIN), exonic rate or sample specific estimate of GC
bias on the expression data and computed the residuals
• Residuals from multiple covariate correction: In each tissue individually, we
estimated expression percent variance R2 explained by the known technical
confounders. Next, using a linear model we regressed the technical covariates
with R2 ≥ 0.01 in a tissue and computed the residuals. (Table 3-I)
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• Residuals from principal components: For each tissue, principal component
based gene expression residuals were computed as described in above.
Prior to reconstructing co-expression networks with WGCNA and graphical lasso,
we transformed the uncorrected and corrected expression of each gene to a Gaussian
distribution by projecting the expression of each gene to the quantiles of a standard
normal.
To reconstruct unsigned weighted co-expression networks with WGCNA, we identified
the lowest power for which scale-free fit R2 between log(p(k)) and log(k) exceeds 0.85.
Here p(k) is the fraction of nodes in the network with at least k neighbors. After that
we used the ‘blockwisemodules‘ function in the WGCNA CRAN package to perform
co-expression module detection at varying cut-heights of hierarchical dendrogram
ranging from 0.9 to 1.0. For networks reconstructed with WGCNA, we considered all
genes in the same module to be a fully-connected subgraph.
For reconstruction of co-expression networks with graphical lasso, we first computed
the gene covariance matrix and then used ‘QUIC‘ function in the QUIC R package to
infer co-expression networks with penalization parameter λ ranging from 0.3 to 1.0.
Evaluation of co-expression networks
To evaluate our correction method and its effect on reconstruction of co-expression
networks, we used two methods to infer the structure of gene co-expression networks:
a) weighted gene co-expression networks (WGCNA)[78] and b) graphical lasso[71] - as
described above. Since the underlying network structure is generally unknown, we
used a) genes known to be functional in the same pathways and b) known transcription
factors and their targets as ground truth to assess these networks.
• Canonical pathway databases: We downloaded the latest pathway infor-
mation (2016) from KEGG, Biocarta and Pathway Interaction Database from
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Enrichr [79, 80], that were also annotated as canonical pathways by MSigDB
[81]. The number of pathways/genesets in each of these databases were:
– KEGG - 293
– Biocarta - 237
– Reactome - 1530
– Pathway Interaction Database - 209
Any pair of genes that have at least one pathway in common were assumed
as true functional relationship. An edge that was observed between a pair of
genes in the inferred network (from WGCNA or graphical lasso) and was also
present in the list of real connections was called as a true positive (TP). We
defined false positive (FP) to be an edge that was observed between a pair of
genes in the inferred network, however was absent in the list of real connections.
Shared true positives: We obtained a refined list of real connections described
above by restricting to pairs of genes that were present in at least two pathway
databases. All TP, FP and FN were computed with genes restricted to the most
variable 5000 genes that were used for reconstructing co-expression networks.
We compute false discovery rate as given below:
FDR = FP(TP + FP ) (3.6)
Results
In this study, we provide a framework for data correction leveraging the structure of
scale-free networks. We show that for scale-free networks, principal components of
a gene expression matrix can consistently identify components that reflect artifacts
in the data rather than network relationships. It has been shown that real world
networks including co-expression networks often have scale-free topology, i.e. the node
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degree distribution of these networks follow a power law[74, 82, 83]. Several studies
have employed the assumption of scale-free topology to infer high-dimensional gene
co-expression and splicing networks[14, 70].
Latent factor-based data correction has been successfully employed in many applica-
tions in genomics from genome-wide association studies, cis- and trans-eQTL mapping,
to differential expression analysis[17, 84–87]. In genome-wide association studies
investigating the association between genotype and complex traits, it has been shown
that the top principal components explain the broad correlation between genotypes
which generally reflects population structure rather than a desired functional biological
signal of interest[87]. Co-expression analysis is more complicated because confounders
affect sets of genes in ways that induce correlation or apparent co-expression. Here, we
show mathematically, through simulation and through real data examples that similar
to genetic association studies, the broad correlation between gene expression levels in
uncorrected data appears to reflect artifacts. We expect that most real co-expression
networks are sparse which means that most genes are only connected to a small subset
of other genes. We prove that when such networks satisfy the scale-free property,
the signals from the network will not be sufficiently broad across genes to influence
the latent variable estimates from PCA. Thus, principal components will primarily
capture latent confounders, which can then be regressed from the expression data
before network reconstruction is performed.
Using a toy and scale-free simulation, we first showed that confounding can introduce
false correlations between sets of genes that can mimic co-expression and can lead to
false edge discovery during reconstruction of co-expression networks with graphical
lasso - sometimes at the expense of losing true connections (Figure3-1). We corrected
the confounded simulated data using our PC based approach and reconstructed the
network using the residuals. Graphical lasso correctly estimated the network structure
obtained from corrected data, which was same as the true network structure that was
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Figure 3-1. Toy Simulation Example. This toy simulation shows the reconstruction
of gene co-expression networks is affected by confounders. (g-i) True underlying network
structure can be reconstructed after principal component correction of gene expression
data as described in the paper
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obtained from the original simulated data (Figure3-1). We also simulated multivariate
gaussian data with 350 samples and 5000 genes from an underlying scale-free network.
Similar to previous simulation, we found that confounding in data can introduce many
false positives in reconstructed co-expression networks. We also showed that networks
reconstructed with PC corrected data in this setting were more similar to original
simulated data compared to confounded data. Throughout our analysis, to estimate
the number of principal components to be removed, we used a permutation based
scheme[76] as implemented in the sva package[84].
To demonstrate the impact of latent confounders and principal component correc-
tion on reconstruction of co-expression networks from real large-scale human gene
expression measurements, we applied our method to RNA-seq data from the GTEx
project v6p release. We considered data from eight diverse tissues containing between
304 and 430 samples each (Table3-I): Subcutaneous adipose, Lung, Skeletal muscle,
Thyroid, Whole blood, Tibial artery, Tibial nerve and Sun-exposed skin. Using the
most variable 5000 genes, we reconstructed co-expression networks for each tissue with
two popular methods: (a) weighted gene co-expression network analysis[70, 78], and
(b) graphical lasso[71, 88]. Since the true underlying co-expression network structure
is not known, we assessed the networks using gene pairs annotated to function in
the same pathways[79, 80] as ground truth edges. We inferred networks obtained
by using a) uncorrected expression data, the residuals after regressing out b) RNA
integrity number (RIN)[89], c) exonic rate - a mapping covariate that corresponds
to fraction of reads mapped to exons[20], d) sample specific estimate of GC bias,
all known to be common confounders in mRNA gene expression data[90–92], and e)
residuals from multiple regression model using covariates that explained at least 1
percent of expression variance (adjusted R≥0.01, TableA-II)[89, 93–95].
Co-expression gene modules obtained from weighted signed co-expression networks
were interpreted as fully-connected subgraphs. For most tissues, networks obtained
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from data corrected for latent confounders showed fewer false discoveries compared to
those obtained from uncorrected data, or from correcting for individual covariates in-
cluding RIN, exonic rate (a quality metric from RNA-seq mapping), or sample-specific
GC bias (Figure3-2(a-c), A-1,A-6, A-2). Improved performance of networks obtained
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Figure 3-2. False discovery rate of WGCNA modules and graphical lasso net-
works based on canonical pathways a–c FDR of WGCNA networks obtained at varying
cut heights. Each point corresponds to FDR of the network obtained at a specific cut
height. Each color represents networks reconstructed with a specific correction approach.
d–f Each point in the figure corresponds to false discovery rates of networks obtained at a
specific L1 penalty parameter value (lambda) in the graphical lasso. Each color represents
networks reconstructed with a specific correction approach—uncorrected, multi-covariate,
RIN, and PC corrected.
from PC corrected data was more evident in whole blood, skeletal muscle, tibial artery,
tibial nerve, subcutaneous adipose and thyroid. But for some tissues such as lung, PC
correction only contributes to moderate improvement on false discovery rates in the
reconstructed networks. It is possible that in these cases, the networks may violate
the scale-free assumption, or that true signal was already sufficiently strong in the raw
data. We also observed that correcting gene expression data with multiple technical
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a b c
Figure 3-3. Module properties of WGCNA before and after PC correction of
gene expression measurements. a) On average the number of genes per module are
considerably smaller in WGCNA after PC correction of data b) The number of modules
identified are different and varies across tissues. The pattern was inconclusive among PC
corrected and uncorrected networks. c) The number of genes assigned to gray module is
considerably higher upon PC correction.
covariates (approximately 9 - 17 were used per tissue, TableA-II) sometimes improved
reconstruction of co-expression networks obtained by WGCNA (Figure3-2(a-c),A-1).
The average WGCNA module size for networks with cut-height greater than 0.99 is
smaller with PC corrected data compared to uncorrected counterparts (Figure 3-3).
We also observed that the number of genes assigned to gray(unassigned) module in
WGCNA was considerably higher in PC corrected networks (Figure 3-3). Finally, we
repeated this analysis by varying multiple settings of WGCNA and found that PC
corrected showed improvement in most tissues consistently.
In graphical lasso networks, we found that networks estimated with principal compo-
nent corrected data showed fewer false discoveries compared to networks estimated
with uncorrected, RIN corrected or multiple covariates corrected data (Figure 3-2,
FigureA-3).
We observed that in general improved performance on false discoveries in PC cor-
rected networks over raw data in whole blood, skeletal muscle, tibial artery and tibial
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nerve. Compared to raw data, jointly correcting the gene expression data for multiple
technical covariates that affect expression measurements also improved reconstruction
with graphical lasso in some tissues such as whole blood, thyroid, and tibial artery,
while it showed little to no improvement over uncorrected data in lung, muscle, tibial
nerve, and sun exposed skin (Figure 3-2, FigureA-3).
However we observed that across all tissues PC correction still shows fewer false
discoveries compared to multiple technical covariate based correction. There was no
visible improvement in network reconstruction between using uncorrected data and
residuals from RIN or exonic rate; thereby suggesting that RIN, exonic rate or GC bias
individually is not a sufficient alternative for the wide range of confounding variation
found in gene expression data (Figure 3-2,A-3,A-7,A-4). We also found that there was
no improvement on false negative rates upon PC correction in networks built with
WGCNA or graphical lasso. With both WGCNA and graphical lasso, networks inferred
from principal component corrected data were much more sparse than networks from
uncorrected, and RIN, exonic rate or GC bias corrected counterparts (Figure 3-4).
Further, PC corrected networks from graphical lasso also showed higher clustering
coefficient, and fewer hubs compared to others.
Conclusion
Network reconstruction methods are vulnerable to latent confounders present in gene
expression data. Co-expression networks obtained from data corrected for effects of
RIN, exonic rate, or GC bias individually show little improvement on false discoveries
compared to uncorrected data and are not a sufficient surrogate for the diverse sources
of confounding variation in gene expression data. With empirical analysis supported
by theoretical proof, we show that PC correction is a simple, yet effective approach to
address confounding variation for reconstruction of gene co-expression networks. We do
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Figure 3-4. Density of the inferred co-expression networks. a-c Each point corre-
sponds to a number of edges in networks inferred by WGCNA at a cut height. d-f Each
point corresponds to a number of edges inferred by graphical lasso in networks obtained at
a specific L1 penalty parameter value. Networks inferred by PC-corrected data have fewer
edges compared to uncorrected or RIN-corrected data
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that may not match the scale-free assumption, or when large differences in expression
changes are expected (e.g. cancer vs normal), removing principal components may
remove biological signal of interest and, as with any data cleaning methodology,
should be used with caution. We have implemented our PC correction approach as
a function - sva_network in sva Bioconductor package which can be used prior to
network reconstruction with a range of methods.
In summary, this chapter shows that known and latent confounders introduce
biases in the form of false correlation structure in gene expression measurements
which leads to a large number of false discoveries during inference of co-expression
networks. Therefore, it is critical to correct the gene expression data to remove
patterns of artifactual variation. PC residualization of gene expression data can adjust




Multi-study integration to identify
global expression patterns and key
regulators of Epithelial to
Mesenchymal transition (EMT) in
cancer
Introduction
Cancer is the second leading cause of death in United States. Metastasis is the leading
cause of cancer-related morbidity and mortality[96], but identifying tumors with
metastatic potential remains a challenge[97]. Tumor metastasis is a multi-step process
in which primary tumor cells disseminate from their site of origin to seed secondary
tumors at a distant site[98]. It is believed that in a critical early event in cancer
progression, metastatic cancer cells undergo an epithelial to mesenchymal transition
(EMT). During EMT, stationary epithelial cells lose cell polarity and transdifferentiate
to spindle-shaped motile mesenchymal cells. EMT is a crucial physiologic process
involved in early development during embryogenesis and organogenesis. It also plays
an important role in tissue regeneration and wound healing. However, in cancer, EMT
may contribute to tumor progression and malignant transformation. Several epithelial
cancer cells have been described to undergo EMT transform to a more malignant
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•  Loss of epithelial features 
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Figure 4-1. Epithelial to mesenchymal transition. During EMT, non-motile epithelial
cells trans-differentiate to mesenchymal cells with increased migratory potential. During
this, cells show decreased expression of epithelial specific genes that include E-cadherin,
OVOL1, and ESRP1. At the same time, expression of mesenchymal genes such as
N-cadherin, VIM, and ZEB1 increases.
phenotype[99] that can further promote formation of secondary tumors[100]. The
role of EMT has been frequently debated in clinical cancer metastasis[101]. However,
several in vitro studies have shown that epithelial cancer cells can undergo EMT in
response to a combination of signals from the tumor microenvironment [97]. During
EMT, cells go through multiple morphological and biochemical changes resulting in
loss of epithelial properties coupled with gain of mesenchymal characteristics[102–116].
Microarrays have been widely used to study gene expression patterns of cell populations
under different experimental settings, including EMT-inducing conditions (Figure 4-1).
While there have been many studies investigating the effect of a gene or pathway in
EMT, none have explored the universal changes across multiple cancer tissue types
or EMT induction methods. Several gene expression datasets examining EMT in a
variety of different cell lines under different conditions are available on open access
databases such as Gene Expression Omnibus (GEO)[117]. It has been demonstrated
that re-use and aggregation of public gene expression data facilitates discovery of
signals too weak to be detected in an individual experiment[118–121]. Gröger et al.
performed meta-analysis of 18 EMT gene expression studies and identified 130 core-
EMT genes, which were differentially expressed in at least 10 of the 18 studies[122].
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Genes such as TGFB, GNG11, TIMP1, ETS1, S100A14, DPYSL3, and C1orf116
that we discovered as differential EMT, were not found in their core EMT gene list.
Furthermore, we experimentally validated some of these genes (S100A14, DPYSL3, and
C1orf116 ) in PC3 epithelial, PC3-EMT and PC3-taxol resistant cell lines confirming
their association in EMT. Also, each dataset in [122] was confined by small sample size
per class (n<=6). The drawback with under-powered studies are: a) low probability of
identifying true effects and b) overestimation of effect size[123, 124]. Therefore, genes
that showed consistent moderate effects across datasets could be missed. In contrast,
systematic integration of multiple studies promotes reliable detection of consistent
gene expression changes that may otherwise be false negatives in results obtained from
individual experiments[125]. At the same time, it helps avoid false discoveries that
could result from intra-study variability resulting from single experiment. Batch effects
and noise introduce spurious signal and correlations in microarray gene expression
data [84, 91, 126]. Therefore, data normalization is crucial in order to correct the
data for unwanted biological or non-biological effects. However, Groger et al. do not
account for batch effects, cross-platform differences, or cross-tissue effects in their
meta-analysis study that could potentially lead to false positive findings. In this study,
to identify universal EMT genes common across multiple cancer types, we integrated
15 independent gene expression studies representing 12 cell lines (49 epithelial and 46
mesenchymal phenotypes) from 6 cancer tissue types and multiple EMT induction
modalities (Table 4-I).
After correcting data to account for cross-study differences, cross-platform differences,
and other sources of noise, we performed differential expression analysis and identified
global changes in gene expression patterns between epithelial and mesenchymal states
(Figure 4-2). Importantly, our candidate gene list was enriched for EMT-related
genes and we identified known markers of EMT. In addition, we also identified EMT





















Figure 4-2. Workflow for multi-study data integration, normalization, and iden-
tification of candidate universal EMT genes.
previously unknown in prostate cancer (e.g. LSR, S11A14, DPYSL3 ), implying a
common EMT program across multiple cancer types. We further identified genes that
had not been previously characterized in EMT in any disease state including C1orf116,
which we then experimentally validated using siRNA knockdown in PC3 epithelial
cells. This approach of multi-study integration enabled identification of differential
EMT genes universal across different types of cancer. Functional validations of these
genes indicate manifestation of molecular mechanisms contributing to EMT shared
across disease types. This study also identifies an uncharacterized candidate novel
EMT regulator gene C1orf116. These findings thereby extend our knowledge and
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understanding of EMT biology.
Methods
Data Overview
We used 15 published EMT microarray gene expression datasets from GEO (Gene
Expression Omnibus) (Table 4-I). This is comprised of 95 observations (45 unique
samples and 50 replicates), 49 epithelial and 46 mesenchymal cell lines exposed to
different treatment modalities. The cell lines come from 6 different tissue types
including breast, prostate, colon, esophageal, liver and retinal pigment and 4 different
microarray platforms (8 chips), Affymetrix, Agilent, Stanford Microarray Database
(SMD) and Illumina. All the datasets were downloaded in the format they were
submitted to GEO. We mapped platform specific probe IDs to Ensembl IDs and gene
symbols. When multiple probes mapped to same gene, we used median values to
represent expression of that gene. We used 7276 genes common across all datasets.
Data Normalization
This work combined data from multiple studies spanning diverse cell lines and different
platforms. Batch effects and noise are inherent in gene expression data. To account
for confounders in data as a result of cross-study and cross-platform effects, we used
multiple correction methods, such as quantile normalization (QN), Surrogate Variable
Analysis (SVA), quantile normalization followed by SVA, and Column Standardized
Median Centered (MCtr). We merged all 15 datasets into one matrix prior to quantile
normalization and SVA. For MCtr, we individually processed each study and combined
them after normalization.
Quantile Normalization: Quantile normalization makes the gene expression
distribution of each sample in the dataset the same. Given a dataset D with g genes
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and n samples, this process:
1. Sorts each column in D
2. Computes the mean for each row and assigns it to each element in the row giving
D′
3. Rearranges columns in D′ such that it has the same ordering as original D, thus
giving normalized data, Dnormalized
At the end of this, each column in D has the same distribution [127].
Surrogate Variable Analysis: Surrogate variable analysis allows us to preserve the
phenotype signal of interest (epithelial and mesenchymal). It estimates known and
hidden confounding factors using Singular Value Decomposition on residual variation
matrix. We regress out estimated surrogate variables from gene expression data to
get SVA normalized gene expression [84]. We also quantile normalize combined data
followed by SVA to correct for hidden confounders.
Column standardized Median centered: Samples from each study are stan-
dardized and median centered by gene as described in [128] and combined them.
Differential Expression Analyses and concordance between nor-
malization methods
With each of the normalized dataset, we used a two-sample t-test to identify differen-
tially expressed genes between epithelial and mesenchymal states. Assuming equal
variance, we compared the mean expression of a gene between the two populations.
For each gene, we tested:
H0 : µe = µm (4.1)
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H1 : µe ̸= µm (4.2)
We ranked genes by raw p-values and applied Bonferroni correction for multiple
hypothesis testing. To test concordance between normalization methods, we used
Spearman’s rank correlation to test association between gene ranks (n = 7276)
obtained by different correction methods. Assuming equal probability of error for
each normalization method, we computed average rank for each gene across the
four methods that represented the consensus position of each gene according to the
differential expression test statistic.
Cluster evaluation of normalized data
To evaluate if normalization improved overall grouping of epithelial and mesenchymal
phenotypes together, we clustered each of the normalized data using hierarchical
clustering (with all 7276 genes). Next, to evaluate grouping we used Baker-Hubert
Gamma index for cluster evaluation. Baker Hubert’s Index (BH) [129] is an adaptation
of Goodman and Kruskal gamma statistic in the context of clustering.
BH = S
+ − S−
S+ + S− (4.3)
Here S+ is the number of concordant quadruples and S− is the number of disconcordant
quadruples. To compute BH, it tests all possible quadruples in the input.
Suppose we were testing quadruple samples a, b, c, d. And d(a, b) is the distance
between samples a and b. A quadruple is concordant if it fulfills one of the following
two conditions:
• d(a, b) > d(c, d); And c and d are in same cluster and a and b are in different
clusters
• d(c, d) > d(a, b); And a and b are in same cluster and c and d are in different
clusters
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A quadruple is disconcordant if:
• d(a, b) > d(c, d); And a and b are in same cluster and c and d are in different
clusters
• d(c, d) > d(a, b); And c and d are in same cluster and a and b are in different
clusters
Since we were interesting in improvement in grouping of epithelial and mesenchymal
samples, we used known phenotype vector as cluster assignment for evaluation.
Gene co-expression module detection using WGCNA
With 200 DE genes from QN+SVA data, unsigned co-expression network was con-
structed using the WGCNA package in R[78]. Since we used differentially expressed
genes, prior to constructing networks, the effect of phenotype (epithelial and mes-
enchymal) from each gene was removed using a linear model.
RT-qPCR
RNA was isolated from cells at 80% confluency using RNeasy kit (Qiagen) and
subsequent cDNA libraries were prepared using Bio-Rad cDNA synthesis kit. TaqMan
gene expression assays were used to determine mRNA expression levels using the fol-
lowing probes: β -actin Hs_1060665_g1, LSR Hs01076319_g1, S100A14 Hs04189107,
DPYSL3 Hs00181665_m1, C1orf116 Hs00539900_g1, OVOL1 Hs00970334, CDH1
Hs01023894, CDH2 Hs00983056_m1, ZEB1 Hs00232783_m1. Relative Expression
Calculations: In the qPCR, the target of interest in each sample is measured using at
least three biological replicates. The Ct value for each biological replicate is calculated
as an average of three technical replicates. Then the Ct value of each biological
replicate is normalized to β -actin by subtracting it from the corresponding Ct value
of β -actin (−∆ Ct). The two groups of interest are compared using a Student’s t-test.
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The values plotted in the graph are the average of the base 2 anti-log transformations
of −∆ Ct for the biological replicates of interest divided by the average of the base
2 anti-log of −∆ Ct for the reference group. The standard errors of the mean are
determined from biological replicates.
Western Blot
Protein extracts were prepared using Frackleton-lysis buffer with protease inhibitors
(Thermo Scientific 78410), and samples were electrophoresed on 4 − 15% SDS-PAGE
(Bio-Rad), transferred to a nitrocellulose membrane and blocked with casein blocking
buffer (Sigma B6429). The list of antibodies used for western blotting is in Table B-I.
The Licor Odyssey fluorescence scanner was used for visualizing the westerns.
siRNA knockdown of C1orf116
C1orf116 siRNA (ThermoFisher, cat#: 4392420) with RNAiMAX transfection reagent
(ThermoFisher) was used for siRNA transfections. Some alterations were made to
manufacturer’s recommended protocol. Cells were seeded at a density result in 50%
confluency the following day. Using a 6 well plate, 9 ul of RNAiMAX reagent and
3 ul (30 pmol) of siRNA (each diluted in 150 ul of Opti-MEM media) was added to
each well the day after seeding. 72 hours later RNA was isolated (Qiagen, Rneasy
mini kit) from plates and gene expression was analyzed.
C1orf116 expression in cancer patient data
We identified publicly available published cancer patient (breast, prostate, esophageal,
liver, colorectal, and lung) gene expression studies with at least 150 patients on
Oncomine[130]. Gene expression data for studies (GSE17536[131], GSE11121[132],
GSE25066[133], GSE22358[134], GSE7390[135], GSE68465[136], GSE31210[137], and
GSE21034[138]) available on GEO were obtained using the GEOquery R package[139].
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Probeset IDs corresponding to C1orf116 were used. Gene level expression was obtained
by aggregating multiple probe expression values with median. Wilcoxon rank sum
test was used to test association between expression of C1orf116 and grade, smoking
status and cancer sample site. We also looked at association between tumor grade and
C1orf116 expression in 4 breast cancer, 1 colorectal cancer and 1 lung cancer studies
from Oncomine. We adjust Wilcoxon rank sum p-values with bonferroni correction
for a total of 23 tests performed for clinical associations.
Results
We identified publically available gene expression microarray datasets that queried gene
expression of cell lines induced to undergo EMT[102–116]. We confirmed the phenotype
of the samples by referring to associated publications for immunohistochemistry
staining and/or protein expression of known epithelial or mesenchymal markers (Table
4-I). 95 cell line observations (45 unique samples and 50 replicates) from 15 datasets
that showed sufficient evidence of correct phenotypic labeling included 49 cell lines of
epithelial phenotype and 46 cell lines of mesenchymal phenotype.
Normalization methods show consistency in signal
Technical variability in the form of noise and batch-effects is inherent in gene expression
data. We performed rigorous confounding factor correction to make gene expression
comparisons between epithelial and mesenchymal samples that came from different
studies, platforms, and cell lines. We used standard normalization methods including
column standardized mean centered (MCtr)[128] and Quantile Normalization (QN)
[127] and more rigorous methods that included Surrogate Variable Analysis (SVA)
[84] and combination of QN followed by SVA (QN+SVA). With each normalization
method (MCtr, QN, SVA, QN+SVA), we compared the mean expression of epithelial
and mesenchymal cell lines by a two-sample t-test for differential expression. We
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GEO ID Platform ID Disease Type Cell line Samples*
GSE12811 GPL7319 Breast MCF10A 3
GSE13915 GPL7785 Breast BT549, EFM19 4
GSE18070 GPL570 Breast MCF10CA1h 9
GSE28569 GPL6480 Breast MCF10A 8
GSE39356 GPL6480 Breast MCF-7 4
GSE8240 GPL3921 Breast MCF10A 11
GSE12203 GPL2700 Colon Caco-2 4
GSE14773 GPL570 Colon HT29, SW480 8
GSE27424 GPL570 Esophageal EPc2-hTERT 12
GSE26391 GPL6244 Liver HCC-1.1, HCC-1.2 8
GSE14405 GPL570 Prostate PC3, TEM4, TEM2 6
GSE22010 GPL6244 Prostate PrEC-hTERT 2
GSE22764 GPL6884 Prostate PC3 6
GSE43489 GPL570 Prostate PC3 4
GSE12548 GPL570 Retinal pigment ARPE19 6
Table 4-I. Dataset Information.
evaluated concordance among normalization methods to determine signal robustness –
any individual method may be subject to false positives due to different patterns such
as outliers, batch effects, etc. For this, we restricted our analysis to 7276 genes that
were common across all studies. We used spearman correlation to test association
between raw test statistics (n = 7276 genes) obtained from two-sample t-test from each
of type of normalized data. Test-statistic distributions from individual normalization
methods were significantly correlated with each other (p-value < 2.2e−16, n=7276).
This indicates that signal produced by data normalized using a particular method
is consistent with others (Figure 4-3). Next, to assess if normalization improved
overall grouping of epithelial and mesenchymal phenotypes together, we clustered
samples from each of the normalized datasets using hierarchical clustering (using all
7276 genes). Next, to evaluate this grouping we used the Baker Hubert Index (BH)
with known phenotype vector as group assignments. Values of the BH index range
from -1 to 1, with larger values indicating better grouping[140]. Table 4-II shows



































































Figure 4-3. Consistency in differential expression signal across normalization
methods. A. Correlation heatmap showing concordance (Spearman rho) among ranks of
differentially expressed genes using the four normalization methods (n=7276). Genes were
ranked by raw t-test p-values. B. Correlation heatmap showing concordance (Spearman rho)
among fold-change of differentially expressed genes using the four normalization methods
(n=7276). C. Hierarchical Clustering of top 200 differentially expressed genes with
uncorrected data shows strong clustering of samples by study rather than by phenotype. D.
Hierarchical Clustering of top 200 differentially expressed genes with QN + SVA (Quantile
Normalized + SVA) corrected data clusters by epithelial and mesenchymal phenotype.
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improved in normalized datasets in comparison to non-normalized data. QN + SVA
performs the best, followed by SVA, MCtr and QN.
No Quantile Surrogate QN Median Centered
normalization Normalization(QN) Variable Analysis (SVA) + SVA Column Scaled
Baker
Hubert Index 0.0001 0.047 0.864 0.7995 0.0705
Table 4-II. Evaluation of sample grouping (with 7276 genes) using Baker Hubert index
and phenotype information.
Differential expression analyses reveal universal EMT genes
across multiple carcinoma types
With every form of normalized data (MCtr, QN, SVA, QN+SVA), we determined
differentially expressed genes between epithelial and mesenchymal cell phenotype by a
two-sample t-test. A gene list ranked by raw p-values from the t-test was generated for
each normalization method. Assuming equal likelihood of error in correction methods
(Figure 4-2), for each gene we assigned a differential rank that was the average of
p-value ranks from all four normalization methods. This was used to generate a final
integrated ranked gene list. We defined a candidate universal EMT gene list by the
top 200 genes from the integrated gene list (absolute fold change > 1.2 and FDR <
0.005 in SVA, QN + SVA and MCtr normalized data) (Table 4-IV). These genes are
representative of global differential EMT patterns independent of cell line origin and
treatment modality.
Cancer cells recruit developmental pathways and processes to acquire migratory and
invasive properties. To determine if the candidate gene list contained groups of
genes working together and shared common biological functions we tested enrichment
it’s enrichment for Hallmark genesets (MSigDB) defined and curated by the Broad
Institute [141] using a right-tailed Fisher’s exact test. The most significantly enriched
gene set was epithelial to mesenchymal transition (Odds ratio = 18.3575636, FDR =
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4.92E-31). Among the other hallmark gene sets, we found increased representation
(FDR < 10%) of several EMT related pathways including estrogen responsive genes
(early and late), genes upregulated in response to low oxygen levels (hypoxia) and
others [5,49–56] (Table 4-III). We also found that specific estrogen responsive genes
(early and late) were differentially expressed even when restricted just to the prostate
cancer samples (Supplementary Figure B-3) indicating this enrichment was not due
exclusively to breast cancer cell lines in our combined analysis. When tested for GO
biological processes, we found enrichment (FDR < 10%) for several developmental
terms including epidermis development, anatomical structure morphogenesis and organ
development. This further confirms that our analyses capture comprehensive signals
in identifying changes in gene expression patterns across cancer types during EMT.
Among genes on our candidate gene list, we found known epithelial- and mesenchymal-
Geneset p-values oddsratio FDR Genes in set
HALLMARK Epithelial 9.84E-33 18.3575636 4.92E-31 CD59, CDH11, CDH2, COL1A1, COL1A2, COL4A2,
mesenchymal transition COL5A1, COL6A3, CTGF, CYR61, DAB2,DPYSL3,
EDIL3, EMP3, ENO2, FAP, FBN1, FBN2,
FERMT2, GEM, GJA1, GREM1, LGALS1, LOX,
MMP14, MMP2, PCOLCE,PCOLCE2, PLAUR, PLOD1,
PMP22, POSTN, SERPINE1, SERPINE2, SLIT2, SPARC,
SPOCK1, TGFB1, TIMP1, VCAN, VIM, WNT5A
HALLMARK Estrogen response late 9.36E-06 4.332224532 0.00019652 ALDH3A2, ASS1, CDH1, CELSR2, LLGL2,
LSR, MAPK13, PLXNB1, RAPGEFL1, SCNN1A,
SLC22A5, SLC27A2, ST14, TOB1, TRIM29
HALLMARK Apical junction 1.18E-05 4.516129032 0.00019652 AKT3, CDH1, CDH11, CLDN7, FBN1, GRB7,
JAM3, JUP, MAPK13, MMP2, MPZL2, PVRL3,
SLIT2, VCAN
HALLMARK UV response dn 8.16E-05 4.23768997 0.001019448 AKT3, COL1A1, COL1A2, CYR61, DAB2, FZD2,
GJA1, HAS2, KCNMA1, MAP1B, PMP22, SERPINE1
HALLMARK Estrogen response early 0.000247578 3.495078664 0.002475779 AQP3, CELSR2, CLDN7, ELF3, GJA1, KRT15,
PMAIP1, RAPGEFL1, SCNN1A, SLC22A5, SLC27A2,
TOB1, WWC1
HALLMARK Hypoxia 0.000436298 3.276838008 0.003635818 AKAP12, CHST2, COL5A1, CTGF, CYR61, ENO2,
ETS1, HMOX1, KDELR3, LOX, PLAUR, SERPINE1, SRPX
HALLMARK Inflammatory response 0.000679488 3.786760716 0.004246802 CD70, CHST2, EMP3, FZD5, HAS2, HRH1,
MMP14, PLAUR, SERPINE1, TIMP1
HALLMARK KRAS signaling up 0.00061698 3.554348835 0.004246802 AKAP12, EPB41L3, ETS1, GFPT2, GNG11, JUP,
MAP7, MPZL2, PLAUR, TMEM158, TRIB2
HALLMARK Angiogenesis 0.003822541 7.2 0.02123634 JAG2, POSTN, TIMP1, VCAN
HALLMARK Complement 0.00451196 3.068992514 0.022559801 CD59, COL4A2, CTSD, MMP14, PLAUR, SERPINE1,
TIMP1, TIMP2, ZEB1
HALLMARK Myogenesis 0.00594623 2.929880329 0.027028319 COL1A1, COL4A2, COL6A3, ERBB3, MEF2C, NCAM1,
PDLIM7, SPARC, TGFB1
HALLMARK TGF beta signaling 0.010673511 4.097902098 0.044472964 BCAR3, CDH1, SERPINE1, SMURF2, TGFB1
Table 4-III. Enriched MsigDB Hallmark genesets.
specific genes such as E-cadherin (CDH1), Zinc Finger E-Box Binding Homeobox
1 (ZEB1), Vimentin (VIM), Transforming Growth Factor, Beta 1 (TGFB1), Tissue
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Inhibitor Of Metalloproteinase 1 (TIMP1)[100, 142], N-cadherin (CDH2) (Table 4-II).
We also observed enrichment of collagen genes that are known to be associated with
cell adhesion and migration amongst DE genes (Fisher’s exact p-value 1.124e-05) [49].
In addition, we also found known EMT related transcription factors such as ZEB1,
ETS1 and LSR in our candidate gene list. We also compared our list of genes to the
core EMT gene signature described by Groger et. al. [122]. We found 43 common
genes from their study (Supplementary Table 4-III). These included genes such as
CDH1, CDH2, VIM, LSR and some collagen genes. Several known EMT genes such
as TGFB, TIMP1, ETS1 that were found in universal EMT genes were missing from
their list. Some other genes such as S100A14, DPYSL3 and C1orf116 (Supplementary
Figure B-1,B-2) that we validate as differential EMT genes in our study, were also not
found in their core gene list.
Candidate gene list identified genes previously unknown in
prostate cancer EMT
In addition to genes well established in the process of EMT, we also identified genes that
had only been described in EMT in a subset of cancer types, including two epithelial
specific genes, lipolysis stimulated lipoprotein receptor (LSR) and S100 calcium binding
protein A14 (S100A14), and one mesenchymal specific gene, dihydropyrimidinase-like
3 (DPYSL3). Previous studies have investigated role of LSR in breast cancer EMT
[143], and S100A14 has been examined in pancreatic and cervical cancer [144, 145].
Previous studies have indicated involvement of DPYSL3 in malignant pancreatic and
gastric tumors[146, 147]. We validated the expression of these genes in an in vitro
model of prostate cancer EMT. mRNA and protein expression levels of these genes
were determined in one epithelial and two mesenchymal prostate cancer cell line PC3
derivatives. PC3-Epi is an expansion of a highly epithelial clone from the parental






















































Figure 4-4. Expression of EMT associated genes in prostate cancer EMT.
macrophage co-cultures (PC3-EMT) and Taxol treatment and subsequent resistance
(PC3-TxR) [115, 148]. RT-qPCR of canonical epithelial and mesenchymal genes,
OVOL1, OVOL2, CDH1, ZEB1, and CDH2, confirmed the appropriate phenotypic
states for these cells lines (Figure 4-4A). Elevated levels of S100A14 mRNA was
observed in PC3-Epi compared to mesenchymal PC3-EMT and PC3-TxR. Similarly,
mRNA expression of epithelial gene LSR was found to be higher in PC3-Epi than in its
mesenchymal counterparts, PC3-EMT and PC3-TxR (Figure 4-4B). Conversely, the
mesenchymal gene DPYSL3 was extremely upregulated in PC3-EMT and PC3-TxR
than in PC3-Epi (Figure 4-4B). These results were supported by western blot analysis,
which demonstrated protein levels mirrored the mRNA expression (Figure 4-4C).
C1orf116 was discovered to be a novel EMT regulator
Our candidate gene list also contained genes that have not been previously described
as related to the EMT process in any cancer type or in any physiologic process. One
of these novel candidate EMT genes, C1orf116 (also known as SARG), is a poorly
characterized gene with only one PubMed listed publication[149]. We first validated
our finding from microarray data using the PC3 in vitro model of EMT and found
increased mRNA expression in PC3-Epi cells compared to PC3-emt (1.3 fold) and
PC3-TxR (8.8 fold). These results were supported by elevated protein expression of
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Figure 4-5. C1orf116: a novel EMT regulator. A. qPCR: mRNA expression of
C1orf116 in EMT model prostate cancer cell lines PC3-Epi, PC3-EMT and PC3-TxR
∗P < 0.1; ∗ ∗ P < 0.05; ∗ ∗ ∗P < 0.005 B. Immunoblot: Protein expression of C1orf116 in
EMT model prostate cancer cell lines PC3-Epi, PC3-EMT and PC3-TxR (LSR, DPYSL3,
S100A14, C1orf116, and β-actin were all probed on the same blot, so the B-actin loading
control is appropriate for both figure 4-4C (LSR, DPYSL2, S100A14) and figure 5B
(C1orf116). Data were separated into two figures for clarity.) C. qPCR: mRNA expression
of C1orf116 and other known epithelial (OVOL1, ESRP1 and CDH1) and mesenchymal
(CDH2) gene in PC3-Epi cells transfected with C1orf116-siRNA relative to empty vector
control ∗P < 0.1; ∗ ∗ P < 0.05; ∗ ∗ ∗P < 0.005
C1orf116 in PC3-epi cells (Figure 4-5A-B).
Increased expression C1orf116 in epithelial cells confirmed of it as an epithelial marker
gene. We applied gene network analysis [78], that revealed weighted coexpression
gene modules (groups of co-expressed genes) and showed that C1orf116 clustered
with other epithelial genes including CDH1, LSR, S100A14 and others (Figure 4-6).
LSR and S100A14 were among the known-unknown genes whose expression was
validated in PC3 cell lines. This confirmed its association with other epithelial genes
universal across other disease types. Through manual literature search, we identified
that a subset of the C1orf116 module gene list have been shown to be associated with
multiple cancer types. Among other genes in the modules, SH2D3A, AP1M2, CDS1
and SCNN1A haven’t been previously studied in cancer biology. This shows that in
addition to being a novel EMT regulator in prostate cancer, C1orf116 could have
broad effects across multiple cancer types. Next, we interrogated the possible role



























Figure 4-6. C1orf116 associated genes in weighted gene correlation network
module. This correlation network shows association of C1orf116 module genes obtained
from WGCNA. Node size is a function of correlation with C1orf116 expression. Yellow
nodes represent genes that have been previously studied in multiple (greater than 3) cancer
types. Bright green nodes are the genes that have been studied in 3 or less cancer types.
Light green nodes are genes that have not been specifically studied in cancer. Gray nodes





























































































































Never smoker Ever smoker
Smoking status
Figure 4-7. C1orf116 expression in cancer patient data. A. Decreased expression of
C1orf116 is seen in metastatic tumor type compared to primary prostate cancer; unadjusted
P = 0.0340, Bonferroni adjusted P = 0.51 B. Expression of C1orf116 decreases in high
grade lung cancer; Bonferroni adjusted P < 0.0005 C. C1orf116 is downregulated in lung
cancer patients with increased smoking habits; unadjusted P < 0.01, Bonferroni adjusted
P < 0.1 D. C1orf116 is downregulated in lung cancer patients with smoking habits in
comparison to non-smokers; unadjusted P = 0.0586, Bonferroni corrected P = 0.879
studies with at least 150 patients that also had information on tumor grade and
expression data for C1orf116 and were able to find breast, prostate, colorectal and lung
cohorts (Supplementary figure B-4). We found that C1orf116 expression is decreased
in metastatic lesions compared to localized tumors in prostate cancer patients (Figure
4-7 A) [137]. Likewise, C1orf116 expression decreased with increasing cancer grade
in patients with lung cancer (Figure 4-7 B) [135]. Studies have shown that lung
cancer patients with history of smoking tobacco/cigarette exhibit lower expression
levels of E-cadherin and higher levels of mesenchymal markers such as vimentin
[150, 151]. Previous studies have also indicated that cigarette smoking can induce
EMT in non-small cell lung cancer[152]. Analogous to these findings, we observed
reduced expression of C1orf116 among lung cancer patients with smoking habits
(Figure 4-7C-D)[135, 136]. In some breast cancer datasets expression of C1orf116
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increased with increasing cancer grade (Supplementary Figure B-4). This suggested
that in addition to expression changes in in vitro cell line models, changes in C1orf116
expression could potentially have a functional role in clinically-important disease
progression in cancer patients.
To test the role of C1orf116 as a driver of an epithelial phenotype, we used siRNA-
mediated knockdown of the gene in PC3-Epi cells. We found that siRNA-mediated
knockdown of C1orf116 expression resulted in decreased expression of epithelial
markers OVOL1, ESRP1, and CDH1, and increased expression of mesenchymal
marker CDH2 (Figure 4-5C). This suggests that C1orf116 plays a functional role in
maintaining epithelial phenotype. Significant upregulation of mesenchymal genes in
response to C1orf116 knockdown indicates it as a novel regulator of EMT.
Test group Wilcoxon rank sum p-value Bonferroni adjusted p-value
Lung cancer (Director’s Lung Challenge): grade [43]
Grade1 vs Grade 2 1.4191e-06 3.27E-05
Grade 2 vs Grade 3 1.1481e-10 2.65E-09
Grade 1 vs Grade 3 2.6121e-17 6.00E-16
Lung cancer (Director’s Lung Challenge): Smoking Status [43]
Never vs Past 0.006 1.38E-01
Past vs Current 0.006 1.38E-01
Never vs Current 0.0002 4.60E-03
Lung cancer (Okayama): Smoking status [44]
Never smoker vs ever smoker 0.0586 1E+00
Prostate cancer (Taylor): Tumor type [45]
Primary vs Metastatic 0.0340 7.82E-01
Table 4-IV. textbfAssociation of C1orf116 expression in lung and prostate cancer patients.
Discussion
EMT may be an early step in cancer metastasis and has been associated with chemore-
sistance and disease progression[153, 154]. Though EMT is common among all solid
tumor types and is essential in early development, common drivers of EMT across
multiple cancer types have not been described. Several studies have investigated EMT
in cell lines from within a single disease type. However, most of these studies have
been confined to very small sample size. To address this, we systematically integrate
multiple EMT studies to increase power and identify novel drivers of EMT universal
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to all cancer types. A significant challenge in multi-study analysis comes from various
sources of heterogeneity arising from study specific technical and biological variation.
Biological variation interferes with analyses, especially when it is not the signal of
interest. We employed two strategies to address various sources of heterogeneity and
noise. First, we chose stringent normalization methods that have been shown to
reduce the influence of such heterogeneity (SVA, quantile normalization, and scaled
median centering). We recognize that these methods may have their failure modes
and limitations. Therefore, we defined our final differentially expressed gene list from
consensus ranking across all four normalization schemes. Thus even if a single method
introduced an error or failed to account for a particular effect, the final gene list may
be more robust than results from any individual method. However, technical variation
and experimental heterogeneity may still influence the results of our analysis, as no
method has been shown to fully remove such effects from expression data. Therefore,
experimental validation and comparison with external functional annotation were
important. Integrating across multiple studies did improve power and helped us detect
novel genes that showed consistent effect across multiple studies, which could be
concealed in a single study. We found three groups of genes in the EMT differentially
expressed list: a) known EMT genes (e.g. CDH1, ZEB1, TGFB, CDH2, VIM, TIMP1),
b) EMT genes previously unknown in prostate cancer (LSR, S100A14, DPYSL3) and
c) novel EMT genes (including C1orf116). We confirmed our discovery of unknown
EMT genes in prostate cancer by testing expression of LSR, S100A14, and DPYSL3
in a PC3 prostate cancer cell line model of EMT. Previous studies have shown that
LSR suppresses EMT phenotype in claudin-low breast cancer cell lines[143]. S100A14
has been studied in breast cancer progression and is showed to be involved in EMT
in human cervical and pancreatic cancer cells[144, 145, 155]. DPYSL3 is associated
with malignant gastric and pancreatic tumors [146, 147]. Moreover studies suggest
that mRNA expression of DPYSL3 is positively correlated with Vascular Endothelial
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Growth Factor (VEGF), a gene thought to be involved in EMT [155]. This data
indicates that our method bridged EMT cancer biology across different disease types
and captures global expression patterns in EMT (Supplementary Figure B-1A-C). We
confirmed discovery of C1orf116 as epithelial specific gene by testing its expression
in PC3 in vitro model of EMT. siRNA knockdown of C1orf116 in PC3 epithelial
cell lines showed loss of epithelial markers and gain of mesenchymal markers thereby
confirming its functional role as a negative driver of EMT. Clinical data from breast,
prostate cancer and lung cancer patients also suggested that changes in expression
of C1orf116 could have functional implications in disease progression. Altogether,
through this study we have found genes whose effects are represented by multiple
cancer types (breast, prostate, liver, colon, esophagus and retinal pigment). We have
also validated expression of some genes in an in vitro prostate cancer cell line model
and potential relevance in vivo data from three tissues, including one (lung) that was
not represented among our cell line data. However, these effects might not necessarily
be extrapolated for cancer types not included in this study. As data become available
for other tissues and cancers, further analysis can be performed.
Conclusion
Using multi-study integration approach, we identified consensus ranked universal
EMT genes. This gene list comprised of a) known EMT genes that included CDH1,
ZEB1 and CDH2 b) genes studied in a subset of carcinomas, unknown in prostate
cancer: LSR, S100A14 and DPYSL3 and c) novel unknown EMT and cancer genes
such as C1orf116. siRNA experiments indicate it to be a potential novel regulator
of EMT. Patient gene expression data shows that reduced expression of C1orf116 is
associated with poor prognosis in lung and prostate cancer (unadjusted Wilcoxon
rank sum p-value < 0.05). In conclusion, our approach of statistical analysis and
functional validation identified universal EMT genes and candidate global regulatory
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genes, thereby both extending current knowledge of EMT and showed preliminary
evidence of disease progression in cancer.
This work demonstrates informed statistical modeling to integrate data from
multiple independent small sample studies can improve power to detect ubiquitous
phenotype associated signal in gene expression measurements. This can also enable dis-
covery of novel genes and biological processes underlying a particular trait, particularly
when large datasets are not available for the trait of interest.
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Chapter 5
Leveraging large scale human




Accurate reconstruction of gene co-expression networks continues to remain a difficult
problem. Reconstruction of co-expression networks over a few thousand genes is of
common interest, particularly to understand the gene regulatory landscape of the the
human transcriptome. Most network learning methods that are based on pairwise
association between genes are sensitive to artifactual variation in gene expression
measurements, and introduce false positive edges in the networks [21, 156]. Further,
with a typical RNA-seq study that contains a few hundred samples, we are highly
underpowered for accurately estimating millions of parameters in a co-expression
network over few thousand genes.
In this study, we leverage > 24,000 uniformly processed and quantified publicly available
human RNA-seq samples spanning 236 studies and tissues from recount2 to build
context-agnostic gene co-expression networks in order to discover shared biological
processes across tissues and cell types in a well-powered analysis [23]. We formulate
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reconstruction of networks as a structure learning task for a Gaussian Markov Random
Field (GMRF), and use the graphical lasso[71] algorithm for inference. Using empirical
covariance C as the input, graphical lasso estimates a lasso penalized precision matrix
Θ by maximizing the penalized log likelihood of a multivariate gaussian distribution.
log det Θ − trace(CΘ) − Λ||Θ||1
It has been demonstrated that aggregation of data across multiple studies can help
improve inference and generalizability of models [157, 158]. While accounting for latent
sources of intra-study and inter-study heterogeneity in these studies, we considered
three strategies of aggregation to obtain an estimate of empirical covariance matrix
that was used as an input to graphical lasso: a) compute empirical covariance by
merging data from all studies, b) unweighted aggregation of individual study specific
empirical covariance matrices, and c) weighted aggregation of individual study specific
empirical covariance matrices. We demonstrate networks obtained by integrating
studies/datasets shows improvement on held-out data likelihood across all aggregation
strategies. Next, we evaluate biological and genetic relevance of topological properties
of the context agnostic network. We find that genes with high degree centrality in
this network are enriched for mitosis and cell cycle related pathways which are needed
in all cell types. We assessed the biological significance of high centrality scores in
14 genesets that included transcription factors, eQTL deficient genes, genes strongly
depleted for protein truncating variations (pLI >0.9), happloinsufficient genes, and
others. Finally, we apply stratified LD score regression to quantify the contribution
of measures of node centrality obtained from context agnostic networks to disease
heritability [159–161].
Contributions
I co-led this project with Prashanthi Ravichandran. My contributions include:
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• Mentoring Prashanthi on designing simulation and empirical experiments for
aggregation strategies, and statistical and biological evaluation of networks
• Download and pre-processing of recount2 data with Prashanthi
• Reconstructing consensus cancer networks with TCGA data from recount2
• Model selection for context agnostic and TCGA networks
• Enrichment of hub genes in mitosis and cell cycle related pathways
• Stratified LD score regression
Methods
Data aquisition, pre-processing and quality control
Raw gene expression RNA-seq counts were downloaded from recount2[23] using the
R package recount. This is comprised of data from Sequence Read Archive (SRA)
including data from the Genotype Tissue Expression (GTEx) project [20] and The
Cancer Genome Atlas (TCGA) project. Raw base level coverage counts for each gene
were transformed to RPKM. Next, we selected for expressed genes by filtering for
RPKM >= 0.1 in more than 25% of samples individually in SRA, GTEx, and TCGA
samples. To overcome erroneous associations that may arise from genes that have
overlapping genomic location, we restrict our analyses to 6871 non-overlapping protein
coding genes with a corresponding gene symbol. We log2(x + 1) transformed RPKM
values, and applied the following sample and study level processing:
• First we selected samples that had metadata information in SRAdb [162], an R
package that has a compilation of metadata associated with datasets in SRA.
• Aggregated multiple runs from the same SRA experiment meaning replicates
using median expression for each gene across the runs.
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• Excluded samples with more than 50% of genes with 0 expression value.
• Excluded potential small RNA expression studies/samples by filtering out sam-
ples with size fractionation based library selection protocol.
• Excluded potential single cell RNA-seq studies based on list obtained by an
abstract search of terms that included. We used the following search terms were
used for the abstract search: "microRNA", "miRNA", and "single cell". The
list of these studies can be found at: https://github.com/princyparsana/
process_recount2_data/blob/master/projects_excluded.rds
• Selected studies or tissues with 30 or more samples.
At the end of this processing, we obtain 14685 observations from SRA studies, 9633 ob-
servations from the GTEx project, and 11284 observations from TCGA. An automated
implementation of this processing pipeline can be found on github.
Aggregation of studies
To systematically integrate information from different studies, we employed aggregation
strategies at different levels of the data as described below: (Figure 5-1):
Study level aggregation: In this approach, we merge all studies into a single dataset
by concatenating the observations. While accounting for intra-study heterogeneity by
applying principal component (PC) residualization as described in [21], we performed
study level aggregation across multiple tissues in GTEx, and studies in SRA. Using
GTEx, we employed an additional study level aggregation where, we accounted only
for inter-study heterogeneity after merging data across tissues. Next, we quantile
normalize each merged dataset such that every gene follows a Gaussian distribution.
We standardize expression measurements so that every gene has zero mean and unit
variance. Finally we compute covariance matrix which is used for network inference.
Covariance level aggregation: In this approach, we first corrected gene expression
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Figure 5-1. Aggregation strategies for integrating co-expression signal across
multiple studies.
measurements in each study or tissue using PC based residualization. Next we perform
the following steps for aggregation:
• Quantile normalize each study such that every gene follows a Gaussian distribu-
tion
• Standardize gene expression measurements in each study such that every gene
has zero mean and unit variance
• Compute gene-by-gene covariance matrix within each study Sk
Assuming equal likelihood of error from each study, we compute the unweighted






where, Sk corresponds to empirical covariance matrix estimated from study k, and |K|
is the total number of studies. Next, assuming that studies with larger sample size
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would have a better estimate of individual covariances, we compute weighted average








wk · Sk (5.3)
where, Sk corresponds to empirical covariance matrix estimated from study k, nk is
the number of samples in study k and wk is the weighted contribution of study k
Co-expression network inference
We reconstructed gene co-expression networks using the empirical estimate of covari-
ance matrix obtained from different aggregation approaches as described above. We
formulate this as a structure learning problem for a Gaussian Markov Random Field
(GMRF), and use graphical lasso as implemented in the QUIC [88] R package for
inference. Assuming that our gene expression data contains N multivariate gaussian
observations each of dimension p, i.e. for each observation, we have expression measure-
ments for p genes, graphical lasso estimates the structure of the co-expression network
over genes by maximizing L1-penalized log likelihood of a multivariate gaussian:
log det Θ − trace(CΘ) − Λ||Θ||1 (5.4)
Here C is the empirical covariance matrix obtained from one of the aggregation
approaches, and Θ = C−1 is the inverse covariance matrix. The L1 penalty on Θ
induces and controls the amount of sparsity in the solution [71]. If an entry Θi,j is 0,
then variable i is conditionally independent of variable j given other variables. We
inferred networks with penalization parameter Λ ranging from 0.2 to 1.0.
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Held-out data likelihood based evaluation of aggregated net-
works
We assess if networks inferred by integration of co-expression signal across multiple
studies improves power to reconstruct reliable and robust co-expression networks using
a held-out data likelihood based appraoch. First we applied aggregation strategies
described above to two splits of data from recount2: a) aggregate across tissues in
GTEx and b) aggregate across studies in SRA (excluding GTEx and TCGA). We
compute held-out data likelihood for each version of SRA aggregated networks using
five tissues with the largest sample size in GTEx. Similarly, each version of GTEx
networks were evaluated using five studies with the largest sample size from SRA as
given below:






In equation 5.5, Li is the held out data likelihood for dataset i, Si corresponds to
empirical covariance matrix from dataset i, Θ is the precision matrix representing the
co-expression network being evaluated, |I| is the total number of datasets used to test
held-out data likelihood. L is the average of held-out likelihood across |I| datasets.
Pathway based evaluation of co-expression networks
We used genes known to be functional in the same pathways as ground truth to assess
precision and recall of the networks. We downloaded the pathway information (2016)
from KEGG, Biocarta and Pathway Interaction Database from Enrichr [79, 80], that
were also annotated as canonical pathways by MSigDB [81]. Table 5-I shows the
number of pathways in each of these database.
Any pair of genes that have at least one pathway in common were assumed to
have a true functional relationship. An edge that was observed between a pair of
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Pathway Interaction Database 209
Table 5-I. Canonical pathway genesets.
genes in the inferred network and was also present in the list of real connections was
called as a true positive (TP). We defined false positive (FP) to be an edge that was
observed between a pair of genes in the inferred network, however was absent in the
list of real connections. All TP, FP and FN were computed with genes restricted to
the most variable 5000 genes that were used for reconstructing co-expression networks.
We compute precision and recall as given below:
Precision = TP
TP + FP (5.7)
Recall = TP
TP + FN (5.8)
Computing gene centrality scores using network structure
Using measures of network connectivity, we compute centrality scores for each gene in
the network. Given a weighted undirected graph G, first we normalize the graph by
dividing the weight of each edge by the maximum of all edge weights in the network.
If E is the list of all edges in the network (excluding diagonals) and Ev,j is the weight
of an edge connecting genes v and j, we get the normalized edge weight Êv,j for this
edge as:
Êv,j = Ev,j/max(Ev,j)
Next, using normalized edge weights, we compute the following types of centrality
scores:
• Degree(v): The degree centrality of a gene v corresponds to the number of
neighbors connected to v
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• Closeness(v): captures how close gene v is to all other genes in the network. For





If v and j are disconnected, then dv,j is set to 0. Using this, we can compute




• Betweenness(v): is the number of shortest paths in the network that pass through
gene v. A shortest path between nodes v and j is a path where the total sum of
the edge weights in the path is minimum.
• Max weight(v): is the maximum of weights of all edges connected to v
• Eccentric(v): is the shortest path distance from the farthest node in the graph
• Eigenvector(v): is proportional to the sum of centrality of neighbors of v. It is
given by:
Ax = λx (5.10)
where where x is the eigenvector of the weighted adjacency matrix A with the
largest eigenvalue λ.
Enrichment and overlap with genesets
We assess the biological significance of high centrality scores in 13 genesets that
correspond to different gene importance related metrics and were obtained from [159].
These included:
1. All genes: This set includes all 19031 protein coding genes according to HGNC
[159].
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2. MGI essential genes: This includes genes for which homozygous knockout in
mice resulted in pre-, peri-, or post-natal lethality.
3. Autosomal dominant genes: Genes among OMIM disease genes that are consid-
ered to follow autosomal-dominant inheritance.
4. Happloinsufficient genes: Genes of severe, moderate, and mild haploinsufficiency,
where having only a single functioning copy of a gene is not enough to carry out
normal functions.
5. High pLI genes: Genes with high probability for being loss-of-function intolerant
(pLI). This list contains genes with pLI > 0.9, meaning that these genes are
strongly depleted for protein truncating variants
6. High shet genes: Genes with high selective effects for heterozygous protein
truncating variants (shet). This geneset contains genes with shet > 0.1, reflecting
strong selection against protein truncating variants
7. High Phi genes: This list included LoF-constrained genes with probability of
haploinsufficiency (Phi) > 0.95.
8. High missense Z genes: These are genes that are strongly depleted for missense
mutations.
9. ClinVar: Genes with a pathogenic or likely pathogenic variant.
10. OMIM genes: Genes obtained from Online Mendelian Inheritance in Man
(OMIM) database.
11. GWAS genes: This list includes genes closest to the peak of a significant GWAS
loci (p ≤ 5e − 8).
12. Transcription factors: This list contains the list of transcription factors.
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13. High EDS: Genes with high score in the enhancer domain score.
include genes with high pLI scores, Genes with high Shet scores, and others. First,
we divide genes with centrality score > 1 into 25 bins ordered by scores. Genes with
centrality score of zero are binned together into one group. Next, using genes in each













where G1 is geneset one of the 14 genesets, G2 is the our test set corresponding to
genes in one of the bins, and Gnet is total number of genes in the network. We compute







Heritablity enrichment with S-LDSC using annotations ob-
tained from measures of network centrality
We applied stratified LD score regression to quantify the contributions of measures
of node centrality obtained from context-agnostic networks in disease heritability.
First we transform all centrality scores to lie between 0 and 1. Next we annotate
SNPs within 100kb of a gene with the centrality score assigned to the gene. If a
SNP was within a 100kb of more than one gene, we assigned the maximum centrality
score to the SNP. We generate six network centrality based annotations and estimate
their heritability enrichment and the standardized effect size (τ∗) of an annotation
as described in [159–161]. Given βj is the effect size of a trait associated SNP j, its






here, τc is the per-SNP contribution of the annotation c to the heritability of the trait.
S-LDSC esimtates τc by fitting the following regression[160, 161]:
E[χ2j ] = N
∑︂
c
ℓ(j, c)τc + 1 (5.16)
here, N is the number of samples in the GWAS, E[χ2j ] = Nβ2j , ℓ(j, c) LD score of
SNP j to the annotation c in the pre-defined window-size (100kb in our analysis).
We compute the standardized effect size (τ∗), i.e. the proportionate change in per-
SNP heritability associated with a one standard deviation increase in the value of







here, sd(C) is the standard deviation of annotation C, h2g is the estimated SNP
heritability, and M is the number of variants used to compute SNP heritability.
Enrichment of an annotation is the proportion of heritability explained by SNPs in
the given annotation divided by the proportion of SNPs in the annotation. In our
analysis we used European samples from the 1000G as reference SNPs, and regression
SNPs were obtained from HapMap3, and SNPs in the MHC regions were excluded.
We conditioned all our analysis on the v2.2 baseline LD annotations. All analyses was
done using hg38 build of the human genome, and relevant files were obtained from:
https://data.broadinstitute.org/alkesgroup/LDSCORE/GRCh38/.
Results
Aggregation of data from multiple studies improves network
reconstruction
To account for study-specific latent artifacts in gene expression measurements, we
PC based residualization as described in [21] to each dataset in our analyses. Next,
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we considered three strategies to aggregate data from multiple studies and obtain
empirical estimates of covariance matrices, which were used to build co-expression
networks with graphical lasso: a) first, we performed a study level aggregation where
we merged corrected expression matrices by concatenating samples from all studies to
form one dataset which was used to compute a gene by gene covariance matrix, b)
second, we computed an unweighted average of covariance matrices obtained from each
dataset, c) third, we computed a weighted average of study-specific covariance matrices
weighted by sample size. We applied this approach to two sets of data from recount2;
one using tissues as a proxy for studies in GTEx with a total of 9633 samples, and
second with individual projects in SRA (excluding GTEx and TCGA) with a total of
14685 samples. (Figure 5-1). We assessed if aggregation of data helps improve power
for inferring gene co-expression networks using a held-out data likelihood approach.
We used the estimated precision matrix (represents networks) from graphical lasso
to evaluate likelihood of held-out studies for each aggregation-dataset pair using a
multivariate Gaussian distribution. Five GTEx tissues with largest sample size were
used as held-out data for networks obtained from SRA, and vice versa. Both with
GTEx and SRA we observe that networks obtained by merging studies or covariances
showed improvement in held-out data likelihood across all aggregation strategies
(Figure 5-2). Reconstructed networks become sparser as we increase the number of
studies that were included in aggregation. Next, using known biological pathways as
ground truth, we compute precision, recall and F1-score for each aggregation-dataset
pair. With aggregation we see consistent improvement on recall and F-1 score, while
we find that precision shows improvement in aggregated networks with higher number
of edges (Figure 5-3). Among the highest level of aggregated networks (50 tissues for
GTEx and 186 studies for Recount), we found that merging studies and weighted
aggregation of covariance matrices yielded very similar networks, which was also




Figure 5-2. Aggregating studies improves recontruction of co-expression net-
works in GTEx (top row) and SRA (bottom row).
previous observations [163]. Both approaches outperformed unweighted aggregation of
covariance matrices (Figure 5-4). For each aggregation strategy, we selected networks
corresponding to a specific value of graphical lasso penalty such that the networks
exhibited a scale-free topology, i.e. node degrees of the network followed a power law
distribution. We adapted the the scale-free test as described in [164] that measures
the variance explained (R2) by fitting a linear model between log(p(d)) and log(d),
where p(d) is represents the fraction of genes in the network with d neighbors. We
selected penalty parameters for networks based on R2 ≈ [0.75 − 0.85]. We find that
networks obtained by merging studies, and by weighted aggregation of covariance
matrix showed high overlap among the top 500 hub genes (Figure 5-5). This was
consistent with our previous observation where we find the two versions of aggregation




Figure 5-3. F1 score of aggregated networks evaluated using canonical pathways
in GTEx(a-c) and SRA (d-f).
Context-agnostic gene co-expression networks: inference and
network properties
While weighted aggregation and merging perform comparably in our analyses, it has
been demonstrated that for effect size estimation, simple pooling of heterogenous
datasets can lead to confounding results, and a aggregation based meta-analysis
approach can protect against such effects [165]. Hence, we chose to reconstruct
context-agnostic co-expression networks using all non-TCGA data from Recount2
a b
Figure 5-4. Comparing across aggregation strategies. a) GTEx, b) SRA
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Figure 5-5. High overlap among the top 500 hub genes across aggregation. The
entries in the heatmap correspond to proportion of shared hub genes. This figure was
generated from SRA networks. Trend was similar in GTEx.
using a weighted aggregation of study-specific covariance matrix as the estimate of
empirical covariance in graphical lasso. This included 186 studies from SRA with
14685 samples, and 50 tissues from GTEx with 9633 samples. Since we found that
networks get sparser over aggregation, we expanded our range of Λ = [0.1, 1] for
building context-agnostic networks. We selected the network corresponding to Λ = 0.2,
which had an R2 = 0.79. This network had 12341 edges over 6871 genes, and had an
average connectivity of 3.59 per node (Figure 5-6). We computed node importance
for genes in the network using different measures of node centrality (See Methods).
Across multiple centrality annotations, we found that few nodes have high scores
(Figure 5-7). We also find that most centrality scores are highly correlated with each
other (Figure 5-8). However, we would take these correlation estimates with caution,
87
Figure 5-6. Context agnostic networks were selected to have scale-free topology.
since it could be inflated by the high number of genes with a 0 centrality score.
Genes with high connectivity in context-agnostic networks en-
riched for annotations of biological importance
Genes with high network centrality are assumed to have wider influence on the
information transfer in the networks, and may be indicative of increased regulatory
relevance. We used the 13 genesets [159] (described in Methods) that are indicative of
increased biological significance to evaluate genes that had high measures of centrality.
For this, we grouped genes into 25 equal bins of ordered centrality scores, and an
additional bin for genes with a score of 0. Next, we compute excess overlap of genes
in each bin with each of the 14 genesets. Genes corresponding to bins with high
centrality scores were enriched for high pLI genes (pLI > 0.9; these genes are strongly
depleted for protein truncating variatns), high Shet genes (Shet > 0.1; these genes
show strong selection against protein truncating variants) [159, 166], genes strongly
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Figure 5-7. Distribution of node centrality scores.
Figure 5-8. Spearman correlation between different node centralities.
89
depleted for missense mutations, and Mouse Genome Informatics essenetial genes
(Figure 5-9). We do not find a conclusive pattern of enrichment for other genesets
(described in Methods) we attempt to evalaute. Exploratory analyses revealed the
hubs of context agnostic networks included multiple mitosis and cell cycle related
genes such as CDK2, TOP2A, CENPE, and CDC20 (Table 5-II). Genes in the top
98th percentile of degree centrality were significantly enriched for mitotic spindle
assembly (OR = 16.23, P = 2.97 × 10−8) and G2/M transition of mitotic cell cycle
genesets from GO biological processes(OR = 8.96, P = 8.90 × 10−6). We compared
this to a tissue-specific skeletal muscle network from GTEx, and do not similar trend
of enrichment. This shows that tissue agnostic networks can capture critical biological
processes that are shared across tissues and cell types.





















Table 5-II. Top 20 hub genes.
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Figure 5-9. Genes with high closeness centrality enriched for genes under strong
selection.
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Figure 5-10. Genes with high degree centrality enriched for mitosis related cell
cycle pathways.
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Enrichment of phenotypic heritability with centrality based
network annotations
Next we attempt to quantify the contribution of centrality based network annotations
to phenotypic heritability. We annotate SNPs within +/- 100kb of a gene TSS using
each of the six measures of gene level centralities. We applied stratified LDSC to
285 independent phenotypes from the UKBB cohort with heritability z-score >=7.
Following guidelines in [160], we also excluded traits with genetic correlation > 0.9.
We find significant enrichment of heritability with each network annotations across
multiple traits. Annotations obtained from betweenness centrality ovreall showed
high enrichment of disease heritability compared to others. (add heritability estimate
and pvals) (Figure 5-11. Estimates of regrerssion coefficients τ∗ were not significant
across individual traits. τ∗ quantifies the estimate of annotation based effect on
heritability of a phenotype conditioned on the baseline LD annotations. This could
imply that though network annotations were enriched for trait heritability, most of it
was captured by the 97 baseline annotations we conditioned the model on.
Next, we meta-analyzed the results of heritailibity enrichments and estimate of
standardized τ∗ across 285 phenotypes using a random effects meta-analysis. For all
six network annotations we find strong enrichment of disease heritability ranging from
1.21(SE0.0213, P < 2.2 × 10−16) to 1.64 (SE0.0323, P < 2.2 × 10−16) (Figure 5-12.
While estimates of τ∗ did not show any significance across individual phenotypes,
upon meta-analyses across phenotypes, it was significant for annotations based on
betweenness centrality (τ∗ = 0.0123, SE = 0.00297, P = 0.0000166). However, we
note that the effect size of esimates of τ∗, were small for all network annotations being
evaluated, including betweenness centrality. Our results from this analyses indicate
that while the six centrality annotations obtained from context-agnostic networks show
enrichment in trait heritability, we only find significant effect of τ∗ with betweenness
centrality with a small effect size.
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Figure 5-11. Distribution of heritability enrichment across 285 phenotypes from
UKBB based on different measures of centarlity.
Conclusion
In a typical RNA-seq study with just a few hundred samples, we are highly under
powered to estimate high dimensional gene co-expression networks. Inconsistent and
missing metadata make it challenging to effectively utilize a large repertoire of publicly
available gene expression studies. With informed probabilistic modeling, these data can
be aggregated across multiple studies to discover shared co-expression patterns across
different biological contexts. Our work shows that aggregation of data across studies
helps improve reconstruction of context-agnostic co-expression networks. Held-out
data likelihood using inferred networks show consistent improvement upon aggregation
across all three strategies. After accounting for study-specific heterogeneity, networks
obtained from merging data and from weighted aggregation of study-specific covariance




Figure 5-12. Heritability enrichment and τ∗ estimates meta-analyzed across
traits.
context-agnostic co-expression networks using data from 50 GTEx tissues and 186
studies in SRA. Hub genes from our networks show significant enrichment of mitosis
and cell cycle related pathways, implying that biological signal identified captures
ubiquitous cellular processes. Further, we find genes with high closeness centrality are
enriched for genesets that reflect strong evolutionary constraints such as those with
high pLI, Phi, and Shet scores. Finally we assess if topological properties of genes in
the network can explain phenotypic heritability using S-LDSC regression. Agnostic
network based annotations show significant enrichment in trait heritability, however
most of the heritability contribution by network annotations is explained by the 97
baselined LD annotations we conditioned our analyses on. Overall, in this work we
show that: a) informed aggregation of public data can improve network inference,
b) context-agnostic networks can provide insights on universal biological processes








The abundance of publicly accessible human gene expression studies available on
databases such as Gene Expression Omnibus (GEO) and Sequence Read Archive
(SRA) is constantly increasing. There have been several efforts to uniformly process
this data, and quantify RNAseq measurements across all publicly available human
RNAseq studies using a standardized pipeline[23]. These databases form an attractive
resource for reconstructing gene co-expression networks. However, inconsistent and
unreliable metadata continue to be a major hurdle in effectively leveraging public
RNAseq studies to improve statistical power.
In this chapter, I describe a hierarchical mixture model groupNet that leverages
multiple datasets to learn the structure of a Gaussian Markov random field (GRMF)
to build context-specific co-expression networks. In absence of reliable meta-data, our
model works by assigning a mixture weight to each study that defines it’s relatedness
to a context. A context can be a biological phenotype such as tissues, cell types, or
disease states. The model borrows strength across studies via a mixture weight driven
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aggregation to estimate context-specific sparse co-expression networks. Preliminary
evidence shows that at reasonable network density, groupNet can correctly identify
study groupings, and shows moderate performance on reconstruction of context-specific
networks
Methods
Background on graphical lasso
Estimating the structure of a sparse high dimensional Gaussian graphical model is
of common interest across biology and statistics. Graphical lasso is one of the most
widely used algorithm for this purpose. Assuming that our gene expression data
contains N multivariate Gaussian observations each of dimension p, i.e. for each
observation, we have expression measurements for p genes, graphical lasso estimates
the structure of the co-expression network over genes by maximizing L1-penalized log
likelihood of a multivariate gaussian given by:
log det Θ − trace(SΘ) − Λ||Θ||1 (6.1)
Here S is the empirical covariance matrix and Θ = Σ−1 is inverse covariance matrix. As
described in the previous chapter, Λ corresponds to the L1 penalty on Θ that controls
the amount of sparsity in the solution [71], and captures patterns of conditional
independence between genes. In our work, we only penalize the non-diagonal elements
of the precision matrix, meaning that the diagonal entries of Λ are fixed to 0.
Next we describe our model groupNet which is a mixture model building on the
network learning principles from graphical lasso.
Problem set up
Suppose we have a database of K independent studies from a publicly available human
gene expression repository. E.g. Recount2. These studies belong to C different tissues,
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however we do not have tissue annotations for study k. Our goal is to first identify
the most likely tissue assignment for study k. We do this by giving soft clustering
assignment to each study-tissue pair. Next, we use these assignments for each tissue
to obtain a context-specific covariance matrix, which is used as an estimate of an
empirical covariance matrix in graphical lasso.
groupNet: model description and inference
Here we describe the mathematical formulation of the model, and derive updates
for parameter inference. We first introduce some notation that we use to describe
groupNet. We use K to denote the set of independent datasets or studies in our
analyses, and C to denote the number of classes that are specified by the group of K







Figure 6-1. Soft-clustering based graphical lasso.
Figure 6-1 is the graphical model representation of our model. ; the variables in
the model in figure 6-1 are described below:
• K is the number of studies/datasets
• each dataset contains Nk samples
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• xnk is p-dimensional vector of gene expression measurements from observation n
from study K. It is drawn from a multivariate gaussian distribution given by:
p(xk,n|zk = c) ∼ MV N(0, Θc) (6.2)
Here Θc is a p × p precision matrix
• Θc has an elementwise Laplace prior:
p(Θc|λ) ∼ Laplace(0, λ) (6.3)
• zk is categorical variable of assignment of dataset K to a context
p(zk = c) ∼ Categorical(ϕc) (6.4)
The joint likelihood of the model in Figure 6-1 is given by:





p(xk,n|zk = c, Θc)
]︄
p(Θc|λ)p(zk = c|ϕ) (6.5)
Since Z ′s are not observed, we marginalize it out, and hence the marginal probability













Next, we take the log of 6.6













If Z ′s were observed, this could be re-written as:








log p(xk,n|zk = c)
]︃
+
log p(Θc|λ) + log p(zk = c|ϕ)
)︃
(6.8)
Since zk is unobserved, we take an expectation maximization based approach for
inference. Given a specific initialization of Θc, we compute the posterior probability
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p(zk = c|Xk, Θc, λ) in the E-step as:
E Step:
p(zk = c|Xk, Θc, λ, ϕ) = γk,c =
([∏︁n p(xk,n|zk = c, Θc, λ)] p(zk = c|ϕ))∑︁
c ([
∏︁
n log p(xk,n|zk = c, Θc, λ)] p(zk = c|ϕ))
(6.9)














log p(xk,n|zk = c)
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γk,c ([nk (− log |Θc| + Tr(SkΘc))] + log ϕc) + Λ||Θc||1 (6.11)
Here, Λ||Θc||1 is the lasso penalty on Θc that comes from the Laplacian prior and





































The above equation can now be solved through graphical lasso. Using an empirical
estimate of the covariance matrix as,∑︁
k wkc · Sk∑︁
k wkc
(6.16)
we used R package glasso to infer the L1 penalized context specific precision matrix.
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Simulation study
We consider a two class problem for this simulation. We first generate two scale-free
networks with p = 1500 genes using igraph R package [167]. Next, given a network
structure, we generate a corresponding covariance matrix as follows[168]:
• Create a p × p matrix with ones on the diagonal, and zeros on elements that do
not correspond to edges
• assign entries corresponding to edges with values from a uniform distribution
with support on {[−0.4, 0.1] ∪ [−0.1, 0.4]}
• Divide each off-diagonal element of the matrix by 1.5 times the sum of the
absolute values of off-diagonal elements in its row. This helps ensure positive
definiteness
• average the matrix with its transpose to get a symmetric positive definite B
matrix




We used this as the estimate of the covariance matrix Σ to generate data from a
multivariate gaussian distribution with mean 0. This simulation setup has been
implemented as an R package netsimulatR and is available on github. We generate
data from six studies drawn from two classes with this framework. Using this data
we reconstruct co-expression networks using groupNet, context-specific average based
graphical lasso, and context-agnostic average based graphical lasso.
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Results
For this experiment, we used six studies drawn from two simulated covariance matrices
as described above. We applied groupNet to reconstruct two context-specific networks.
Preliminary evidence shows that groupNet captures context-specific co-expression
patterns and correctly clusters related studies together into the same group. groupNet
shows performance comparable to class-specific average based graphical lasso on the
number of true positive and false positive edges. Upon evaluation on sum of squared
error of edge values of the inferred network with ground truth, we find that if a
context is known, a class-specific average based graphical lasso shows lowest squared
error, followed by networks obtained from groupNet. Context-agnostic average based
graphical lasso shows the worst performance on both true positives vs false positives,
and squared error. This experiment provides preliminary evidence that: a) groupNet
can identify patterns of context-specific co-expression and group studies by context,
and b) it can reconstruct co-expression networks while capturing context-specific edge
information.
Figure 6-2. Performance of groupNet using simulated data. a. The number of
edges correctly identified to be non-zero (TP) is plotted against the number of edges
incorrectly classified as non-zero (FP) b. The sum of squared error in edge values is shown
against log10(number of edges).
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Conclusion
In this chapter we present a probabilistic method that in the absence of reliable
metadata in publicly available RNAseq studies, can learn latent assignments for each
study and jointly infer context-specific GCNs by sharing information across related
studies. We describe the model, and derive updates for parameter inference. Finally,
using a small simulation analyses, we provide preliminary evidence that that at a
reasonable network density groupNet correctly clusters studies into context-specific




Conclusion and future directions
In this chapter, we will first summarize the work presented in this thesis and next
discuss some future direction and extension of this work.
Summary of contributions
The ability to sequence the entire human genome and to quantify expression of over
40,000 genes from hundreds of individuals provides an extraordinary opportunity to
learn phenotype relevant genomic patterns that can expand our understanding of
molecular and cellular processes underlying a trait. The nature of high-dimensional
genomic data presents a range of computational and statistical challenges. The work
in this thesis attempts to address two major difficulties in this domain: a) artifacts
and noise in transcriptomic data, and b) limited statistical power.
Gene expression measurements are routinely affected by noise and artifacts that intro-
duce spurious structure in the data that can lead to erroneous downstream conclusions.
In chapter 2, we perform an extensive analysis to understand the contribution of known
and latent confounders on gene expression and its effects on eQTL mapping. Next,
while accounting for latent artifacts, we discovered 673 trans-eQTLs across 16 human
tissues, characterized some trait associated trans-eQTLs, and hypothesize potential
functional mechanisms. In chaper 3 we demonstrate that commonly used network
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learning methods are vulnerable to noise and artifacts in gene expression data thereby
introducing a large number of false positive edges. We present a principal component
based residualization method to address the effect of confounders in reconstruction of
gene co-expression networks. Using empirical data, and in simulation we show that
applying PC based correction prior to network learning reduces false discoveries in
reconstructed networks.
In the next part of the thesis, we present methods and strategies to leverage multiple
related studies to increase statistical power in transcriptomic analyes. In chapter 4 we
present a multi-study integration based approach to identify global gene expression
patterns underlying epithelial to mesenchymal transition (EMT) phenotype across
different types of cancer cell lines. We demonstrate that leveraging data from mul-
tiple studies can enable identification of universal phenotype associated genes. Our
comprehensive approach of statistical analysis and functional validation in this work
identified global expression patterns in EMT and candidate regulatory genes, thereby
both extending current knowledge and identifying novel drivers of EMT phenotype.
In chapter 5 we present an aggregation based approach to build context-agnostic gene
co-expression networks. Using data from > 250 datasets from Recount2, we sought to
discover shared patterns of essential biological processes across tissues and cell types.
We demonstrate that agnostic network central genes are enriched for evolutionarily
constrainted genesets, and mitosis spindle formation related GO processes. We find
that network central annotations also show strong enrichment for phenotypic heritabil-
ity in multiple disease relevant traits such as blood and cardiovascular phenotypes in
the UKBB. In chapter 6, we present a mixture model based probabilistic framework
groupNet to reconstruct context specific gene co-expression networks by leveraging
unstructed RNAseq data from public resources. Building on the hierarchical structure
of biological phenotypes groupNet learns latent assignments for each study and jointly
infers context-specific networks by sharing information across studies from related
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phenotypes. Using a small simulation, we show preliminary evidence that groupNet
can capture patterns of similarity across datasets with moderate performance on
network reconstruction. Overall this thesis presents a compilation of diverse projects
that were driven by the motivation to efficiently capture gene regulatory patterns in
the human transcriptome while addressing statistical and computational challenges
that accompany this data.
Future directions
We are far from the dream of fully characterizing genetic and transcriptomic basis of
gene regulation, and understanding the underpinnings trait manifestation in humans.
While we have tried addressing some challenges in inferring high dimensional gene
networks, it still continues to remain a daunting task. However, if one can accurately
infer functional gene relationships in the human transcriptome, they can serve as
powerful tools for: a) understanding the molecular and cellular basis of phenotypic
variability, b) discover discover disease linked causal genes, c) identify relevant genes
or groups of genes for drug discovery, d) discover interpretable biomarkers for patient
stratification based on context specific patterns of differential co-expression. Next we
describe three potential future directions based on the work described in this thesis.
Identifying causal gene regulatory circuits by modeling small
variable sub-problem
Inferring directed gene-gene relationships can help discover causal regulatory mech-
anisms of gene expression. While learning the structure of a Gaussian undirected
graphical model to construct co-expression network is a hard, learning the structure
of the bayesian network is even more challenging. Artifacts in gene expression data,
and statistical power continue to remain a hurdle, further the huge search space that
grows exponentially with the number of nodes in a graph is an additional caveat
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with directed networks. There have been studies that propose several approaches to
reduce the size of the search space for directed networks. Leveraging the topology of
an undirected network can enable identification of a finite set of possible structures
for a directed graph. One can utilize the topology of undirected graphs to identify
small groups of genes This along with sparsity inducing structured priors can further
assist in accurate inference of gene regulatory circuits as gaussian directed acyclic
graphs. A potential extension to chapter 5 could be to identify causal relationships in
context-agnostic processes identified in the study.
Integrating genomic annotations to build a multi-modal prob-
abilistic model for co-expression
Our work in chapter 5 using stratified LD score regression demonstrates that while
network based annotations were enriched for explaining trait heritability, their individ-
ual contribution was almost completely explained by the 97 baseline LD annotations.
Several studies have shown the value of integrating genomic annotations to improve
variant interpretation and to predict the deleterious impact of common and rare
genetic variation. While there have been efforts to integrate multi-modal genomic
data to construct co-expression networks, leveraging genomic annotations to con-
struct structured priors in a probabilistic framework may have the potential to enable
inference of more accurate gene-gene relationships.
Network based models for clinical genomics
Disease biomarkers play a vital role at several stages of clinical decision making such
as: i) predict patient response to treatment or intervention (predictive), ii) predict
patient outcomes (prognostic), and iii) identify if patient has a specific disease or
subtype of a disease (diagnostic). Despite the abundance of nucleic acid biomarkers
reported in literature, there has been little success in translating them to the clinic.
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Further, most of the currently used Laboratory Developed Tests are not able to explain
the underlying molecular mechanism disease manifestation. The probabilistic model
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Appendix A
Addressing confounding artifacts in
reconstruction of gene
coexpression networks
A.1 Conditions for and Proof of Convergence of
Principal Components
Lemma: Let X be a high-dimensional matrix of expression data with signal both
due to artifacts A, and due to a genuine network of linear expression relation-
ships. Then under the conditions below and provided that the node degree distri-
bution of the network follows a power-law, the principal components of X consis-
tently estimate a linear space spanning the artifacts A and not the network structure.
Proof:
Decompose a gene expression matrix with n samples and m genes Xm×n =
(x1, ...., xm)T as follows:
X = µ × 1 + ΓAA + ΓNN + U
where,
• µ = (µ1, ....., µm)T is an m dimensional column vector with µi := E [xi], i =
146
1, ...., m and 1 is an n dimensional row vector of 1’s.
• There are L artifacts or confounders (L < n), forming an L × n matrix A with
an associated coefficient matrix ΓA.
• N is an m × n matrix of expression data without any network structure, with
associated m × m coefficient vector ΓN . Features i and k are share an edge if γNik
or γNki are nonzero. This represents a linear relationship between the expression
levels of genes. To avoid circularity, the diagonal entries of ΓN are set to zero.
• U is an m × n matrix of pairwise independent mean zero random noise
Based on our previous work [169], given a high-dimensional matrix with the number
of features much larger than the number of samples (m >> n) we make the following
additional assumptions about the behavior of the data in the experiment.
1. The number of non-zero entries in the network ΓN follows a power-law distri-
bution with an exponential coefficient 2 < α < 3 [82]. As we point out in the
main text power-law degree distributions have been observed in gene expression
networks, for example yeast co-expression networks [74, 83] and Caenorhabditis
elegans [170], and the preferential attachment model characteristic of scale-free
networks has been explained by gene duplication [171–173]. Further, network
inference algorithms such as WGCNA also employ this assumption.
2. The entries in the artifact and network coefficient, pre-network expression data,























































This is true for most common distributions used to model gene expression data
or a suitably transformed version.





AT ΓTAΓAA − AT ∆A∥F = 0
(b) AT ∆A has eigenvalues λ1 > .... > λL > λL+1 = .... = λn = 0
This assumption means that the batch effects and other artifacts are sufficiently
widespread as to affect a fixed and non-negligable percentage of the genes in the
data set.
Additionally, we assume without loss of generality, that expression levels of each gene
in X is centered.
4. µ = 0⃗.
5. The expression data in the absence of any network structure, N , has mean
E [N ] = 0⃗ where 0⃗ is an m-dimensional column vector. Further, in the absence of
network structure, the genes are pairwise independent. Therefore, by Assumption
2 the entries of N converge almost surely to zero.
Based on this model, we show that the principal components of the matrix X (with
a fixed n - sample size) estimate the artifacts and are not corrupted by the signal
from the network terms.
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The eigen-vectors of the matrix 1
m
XT X are equal to the right singular vectors of
the matrix X. Given observed data X, the empirical variance-covariance matrix of
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m
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We will show that as the number of features (i.e. genes) grows, the empirical
variance-covariance matrix, after centering by an estimate of the background variation,
converges to the same thing as if there were no network structure:
X̃unstr := ΓAA + U.
Then we can show that the principal components of the confounded matrix are
consistent estimators of the confounding variables.
Therefore, we will show that, holding the number of observations n fixed, there













XT X − σ̂2aveI = L
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where, borrowing the notation from Leek 2011, we let VL(X) = {v1(X), ...., vL(X)} be
a matrix of the first L right singular vectors of X and Γ̂L the least squares estimates
from regressing X on VL(X). Then, we define:
σ2ave :=
1
m(n − L)∥X − Γ̂LVL(X)∥F ,
where we estimate L using a permutation approach through the ‘num.sv’ function in
the sva package.
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Leek 2011 shows that the terms limm→∞ 1mA
T ΓTAU + limm→∞ 1mU
T ΓAA both converge
almost surely to zero by the Kolmogorov Strong Law of Large Numbers (KSLLN).
Further, Leek 2011 uses KSLLN to show that the off diagonal elements of 1
m
UT U









X̃unstr − σ̂2aveI = AT∆A,
and
L = AT ∆A.
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We first consider Q := 1
m
ΓTAΓN , an L × m matrix with entries indexed by
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Suppose that there are 0 ≤ d ≤ m indices j for which γN j,k ̸= 0, so that there
are d terms γAj,lγNj,k in the summation contributing to qlk. We can re-index
these terms as γAj′,lγNj′,k , j
′ = 1, ..., d.
For any fixed k, whenever γNj,k , necessarily genes k and j share an edge. Therefore,
given d non-zero coefficients γNj,k , gene k has at least degree d. However, [174]
show that for scale free networks following a power-law degree distribution
pk ∼ kα−1, as assumed in our framework, the maximum degree of a vertex in
the network follows kmax ∼ m
1
α−1 , and d ≤ m
1































































By Assumption 1 (2 < α < 3), so that α−1






Now, consider the expectation of the terms inside of the summation. For any j′,



























B′γA × B′γN By Assumption 2
= B∗ where we define the bound B∗ :=
√︂
B′γA × B′γN ,
and




≤ B∗ < ∞,




























Recall, the matrix of artifacts A is L × n dimensional, so that it is fixed with




























We will first consider P := 1
m
ΓTNΓN , an m × m matrix with entries indexed by













We will consider the diagonal and off-diagonal entries of P separately. The



























Now, whenever γNj,l ̸= 0, by definition, genes j and l share an edge, so that d′,
the number of j such that γNj,l ̸= 0 is equal to the degree of vertex l. Following
the argument from the proof of (1) , d′ ≤ m
1























































and for each l:




































{j:γNj,l ̸=0 and γNj,k ̸=0}
γNj,lγN j,k
If both γNj,l ̸= 0 and γNj,k ≠ 0 then gene j shares and edge with both genes l and
k, so that d′, the number of j such that γNj,l ≠ 0 and γNj,k ̸= 0 will be bounded
by the maximum of the degrees of vertices l and k. The same argument as used



















Further, for any j′, by Assumption 2 and the Cauchy-Schwarz inequality to




























































Therefore, both the diagonal and off-diagonal entries in P converge to zero, and
P
a.s.−−→ 0.












This term converges almost surely to zero by the KSLLN since E [U ] = 0 and







This term converges almost surely to zero by the KSLLN since E [U ] = 0 and
ΓN and U have bounded fourth moments.
Therefore, all of the terms (1)-(5) converge almost surely to zero and the limit of the





XT X − σ̂2aveI = AT∆A + limm→∞
1
m

























NT ΓTNU⏞ ⏟⏟ ⏞
(5)
= AT ∆A = L
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The principal components of this matrix consistently estimate the space spanned
by the confounding artifacts as we have previously demonstrated [169].
Therefore we show that given confounded high-dimensional gene expression data
where the number of genes is much larger than the number of samples - top principal
components will consistently estimate artifacts, and not network structure.
A.2 Effect of fewer PC correction on reconstruc-
tion of co-expression networks with WGCNA
and graphical lasso
Since broad trends in co-expression may sometimes reflect distant regulatory relation-
ships between genes,to ensure that we are not removing true long range signals, we
also reconstructed networks with data corrected for one quarter and half the number
of PCs estimated by our correction method. With WGCNA, we found that using a
half of the estimated number of PCs sometimes performed better in lung and skin.
For the remaining tissues half-PC correction does reduce false discoveries compared
to uncorrected data, however using the complete number of estimated PCs performs
better (Supplementary Figure 6).
With graphical lasso networks, correcting data with fewer PCs does improve FDR
compared to uncorrected data. However, the networks built with data corrected with









[175] WGCNA known technical factors - RIN, pH, PMI, age,
batch, preservation, and gender
[15] WGCNA none
[176] WGCNA none, voom normalization
[177] WGCNA none, quantile normalization
[178] WGCNA none, quantile normalization
[179] WGCNA batch correction
[180] WGCNA none prior to network reconstruction. After
networks were reconstructed, tested for con-
founding through module eigengene-trait corre-
lations. however these did not include technical
confounders like batch, etc.
[181] WGCNA none, tmm normalization
[182] Bayesian bi-
clustering
network learning method jointly models hidden
confounders
[183] WGCNA known technical covariates: diagnosis status,
Age of death, sex, PMI, pH, RIN, clustered




[184] WGCNA batch correction
[185] WGCNA none, quantile normalization






- Code for BSS collection site
- RNA integrity number (RIN)
- Type of nucleic acid isolation batch
- Estimated library size
- Mean coefficient of variance
- Transcripts detected
- Intronic rate
- Expression profiling efficiency
- # transcripts that have at least one read in their 5’ end




- Code for BSS collection site
- RNA integrity number (RIN)
- Type of nucleic acid batch
- End 2 mapping rate




- % intragenic End 1 reads sequenced in sense direction




- Code for BSS collection site
- Type of nucleic acid isolation batch
- chimeric pairs






- Mapped unique rate of total
- % intragenic End 1 reads sequenced in sense direction
- # transcripts that have at least one read in their 5’ end
- Duplication rate of mapped
- Gene GC%
Thyroid
- Code for BSS collection site
- Autolysis score
- Type of nucleic acid isolation batch
- RNA integrity number




- Reads designated as failed by sequencer
- Transcripts detected
- Intronic rate
- Expression profiling efficiency
- # transcripts that have at least one read in their 5’ end
- Duplication rate of mapped
- % intragenic end 2 reads sequenced in sense direction
- Gene GC%
Whole Blood
- Mapped read count
- Code for BSS collection site
- RNA integrity number (RIN)
- Time point reference for Start and End times of sample
procurement
- Chimeric pairs
- 5’ 50-base normalization
- 3’ 50-base normalization
- mean coverage per base
- Library size
- Reads designated as failed by sequencer





- % intragenic end 2 reads sequenced in sense direction
- Gene GC%
Table A-II. Known covariates regressed from gene-expression data for multiple covariate
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Figure A-1. False discovery rates of WGCNA networks obtained at a varying cut-heights
with uncorrected, RIN corrected, multiple covariate corrected and PC corrected data. Most
tissues show considerable reduction in false discoveries after PC correction. PC correction
shows only moderate improvement on FDR in sun-exposed skin.
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Figure A-2. False discovery rates of WGCNA networks using shared list of true positives
obtained from canonical pathway database (gene pairs present in at least two pathway
databases). Each color corresponds to the correction approach, and each point in the
figure corresponds to FDR of the network at specific cut-height.
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Figure A-3. False discovery rates of graphical lasso networks using canonical pathway
databases. Networks were obtained at a varying values of penalty parameter (0.3 - 1.0).
Each color corresponds to the correction approach, and each point corresponds to the
network obtained at a specific lambda.
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Figure A-4. False discovery rates of graphical lasso networks using shared list of true
positives obtained from canonical pathway database (gene pairs present in at least two
pathway databases). Each color corresponds to the correction approach, and each point in
the figure corresponds to FDR of the network at specific value of penalty parameter value
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Figure A-5. Principal component loadings of gene expression are significantly associated
with estimates of sample specific GC bias. Association was tested using a linear model.
Panel (a) shows BH adjusted p-values and (b) shows R-squared.
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Figure A-6. False discovery rates of WGCNA modules using canonical pathway databases.
Each color corresponds to the correction approach, and each point in the figure corresponds
to FDR of the network at specific cut-height. Exonic rate and gene GC% are the known
confounder used in this figure.
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Figure A-7. False discovery rates of graphical lasso networks using canonical pathway
databases. Networks were obtained at a varying values of penalty parameter (0.3 -
1.0). Each color corresponds to the correction approach, and each point corresponds to
the network obtained at a specific lambda. Exonic rate and gene GC% are the known
confounder used in this figure.
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Figure A-8. False discovery rates of networks inferred with signed WGCNA networks
using canonical pathways. Each color corresponds to the correction approach, and each
point in the figure corresponds to FDR of networks obtained at different values of power





































































































Figure A-9. Graphical lasso networks reconstructed after PC correction of gene expression
measurements show higher clustering coefficient compared to uncorrected networks across












































































Figure A-10. Graphical lasso networks (λ = [0.3, 0.43]) reconstructed after PC correc-
tion of gene expression measurements show considerably fewer hub nodes compared to
uncorrected networks across all tissues. Scale-free networks have few hub nodes.
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Figure A-11. Graphical lasso networks reconstructed before and after PC correction of
gene expression measurements show no improvement on false negative rates.
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Appendix B
Multi-study integration to identify
global expression pat-terns and key
regulators of Epithelial to
Mesenchymal transition (EMT) in
cancer
B.1 Supplementary Figures
Figure B-1. Expression of EMT genes previously unknown in prostate cancer in integrated
cell lines data Expression of LSR (A), S100A14 (B) and DPYSL3 (C) in breast, prostate





















Figure B-2. Expression of C1orf116 in breast, prostate and others (retinal pigment, liver,
colon and esophageal) cancer cell lines from integrated data.
Estrogen Response genes: early (prostate samples) Estrogen Response genes: late (prostate samples)
A. B.
Figure B-3. Expression of Estrogen responsive genes - (A) early and (B) late in prostate

































































Smith Colorectal Cancer: gradeD. E.
Hatiz Breast Cancer: gradeGluck Breast Cancer: grade








Anti-beta-actin (A5411) 680RD Goat anti-mouse IgG (H+L) (926-6870)
Table B-I. List of antibodies
Gene Average rank Gene Average rank
MAP7 15 HJURP 190.25
FXYD3 17.5 SPINT1 191.75
EMP3 18 RASA3 195
VCAN 19.25 FAAH 198
ACSF2 30.5 HRH1 198.25
GEM 33.75 GREM1 199
EPS8L2 34.875 MTUS1 199.25
MEF2C 35 ITM2C 199.5
MMP28 35 PLAUR 199.5
LSR 35.75 DSP 203
CDH2 36.25 JAG2 203
ZEB1 36.75 CTSD 203.25
SPOCK1 40 CD320 203.5
COL4A2 40.25 WWC1 203.5
FBN1 40.5 STAP2 204
PPL 42.25 SH2D3A 204.25
PTN 44.75 CHN1 205
GNG11 46 CTGF 206.75
GFPT2 46.5 MST1R 206.75
RGL1 46.5 COL1A2 207.5
PMP22 49.25 EML1 208.25
COL5A1 51.25 SLC22A5 209.75
ASS1 52.75 CXADR 212.25
CDH1 58 LIMK2 212.75
EXTL2 60.375 PLOD1 212.75
ERMP1 60.75 HOOK2 213.375
LLGL2 67.25 MMP14 216
KDELR3 67.75 PEA15 218.5
JUP 70.25 LOX 219.25
RAPGEFL1 74.25 EPB41L3 222.25
ELF3 74.75 MPZL2 222.25
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CLDN7 76.75 HAS2 222.75
SLIT2 77.25 KIRREL 224.75
MYO5C 80.75 PPFIBP2 224.75
MLLT11 81.75 ETS1 226.75
EDIL3 84.375 RHOQ 228.25
CELSR2 84.75 FJX1 228.375
SLC27A2 84.75 INADL 234.75
AKAP12 85.5 FBXO5 236
TIMP1 86 FOXG1 236.75
GLS2 87 TRIB2 238.75
DPYSL3 89 KCNMA1 239.25
COL6A3 90.25 PTPRF 243
SRPX 90.75 VIM 244
PCOLCE2 99.75 PVRL3 245
MAP1B 102 GJC1 245.25
TUBA1A 102.25 AP1M2 247.5
KRT15 105.5 FERMT2 247.5
EPB41L4B 105.75 SMURF2 249.125
FAM64A 110.25 POSTN 249.75
ST14 111 ORAI2 249.875
SLC22A4 111.5 LRBA 250
AKT3 115.25 RBMS3 252.5
FAP 117.5 CEP170 253.375
PDLIM7 117.5 FBN2 254.5
SNAPC1 119 CD70 254.75
HMOX1 120 BCAR3 255
HEY1 121.75 CHMP7 255.25
CLMN 122 GJA1 256.25
ALDH4A1 124.375 DDR2 258
RECK 125 SERPINE1 261.5
GRB7 126 SERPINE2 261.5
CXCL3 126.5 MOXD1 265.25
TIMP2 127.75 MCAM 265.5
TCF4 129.5 SHCBP1 266
CHST2 131 TMEM158 267.25
TRIM29 132.75 RAB25 267.5
PMAIP1 133.75 DAB2 269
OAS1 135 MBNL3 270.125
C1orf116 136 IL1RN 270.5
TOB1 138.25 COL1A1 272.25
LPAR2 138.5 DAAM1 273.5
CDH11 140 AQP3 274.625
ALDH3A2 144.5 MMP2 275.5
TRIM26 145.75 CLPX 279
ABCA12 146 PSIP1 280.75
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S100A14 146.75 DHRS1 281.25
LHFP 150.875 NMNAT2 283
AP1G2 152.25 TWF2 283.25
CDS1 152.875 ZEB2 283.875
TGFB1 154.75 PCOLCE 284.5
HSD17B8 156.75 BCL2A1 284.75
ERBB3 157.375 VAMP8 284.75
SPARC 164.25 SLC2A9 285.75
GLT8D2 166.125 NAV1 286
NCAM1 169 DTX4 288
PKP2 170.5 ENO2 290
SLC35D2 172.5 SLC25A37 290
COL6A1 172.75 ANTXR1 292.75
CYR61 173.25 CASK 294.75
FZD5 173.5 LGALS1 300.5
PLXNB1 173.5 TSPAN5 300.75
LRP8 177 CREG1 305
LRRC1 177.25 FZD2 306.25
WNT5A 179.5 SCNN1A 306.375
MAPK13 180 DDR1 307
JAM3 181 CLN3 308.375
CD59 183 ECH1 310
PRSS8 183.5 SLC27A3 314
SULT1A1 189.25 CEBPA 314.5
Table B-II. List of top 200 ranked differentially expressed genes













































Table B-III. Common genes with Groger et. al. study and 200 DE genes
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